The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

4-2018

Discovery and effects of pharmacological inhibition of the E3
ligase Skp2 by small molecule protein-protein interaction
disruptors
John K. Morrow

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicinal Chemistry and Pharmaceutics Commons, Pharmaceutics and Drug Design
Commons, Pharmacology Commons, Structural Biology Commons, and the Therapeutics Commons

Recommended Citation
Morrow, John K., "Discovery and effects of pharmacological inhibition of the E3 ligase Skp2 by small
molecule protein-protein interaction disruptors" (2018). The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 861.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/861

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

Approval page
Discovery and effects of pharmacological inhibition of the E3 ligase Skp2 by
small molecule protein-protein interaction disruptors
by
John Kenneth Morrow, M.S.

APPROVED:

_____________________________________________
Advisory Professor, Shuxing Zhang, Ph.D.

_____________________________________________
Varsha Gandhi, Ph.D.

_____________________________________________
Scott Gilbertson, Ph.D.

_____________________________________________
Zhimin Lu, Ph.D.

_____________________________________________
Giulio Draetta, Ph.D.

APPROVED:
___________________________________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences

i

Title page
Discovery and effects of pharmacological inhibition of the E3 ligase Skp2 by
small molecule protein-protein interaction disruptors

A
DISSERTATION
Presented to the Faculty of

The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences

In Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHILOSOPHY

By
John Kenneth Morrow, M.S.
Houston, Texas
May 2018

ii

Dedication

This work is dedicated to my mother, Jeanne Morrow, who has always been
supportive in my journey through my scientific career, and love for me knows no
bounds. My father Philip Ross Morrow, whose passion for science and sudden
passing from a rare form of cancer is my primary motivation to go into this field.
Finally, to Angie Marie Torres-Adorno, who has loved, inspired, encouraged,
motivated and supported me on whatever decision I have made.

iii

Acknowledgements

I would like to acknowledge all the hardworking researchers in Dr. Shuxing
Zhang’s lab, Dr. Shuxing Zhang himself who has mentored me through the last nine
years, and who pushed me to achieve great things. Also other lab members including:
Rajan Chaudhari, Beibei Huang, Michael Cato, Zhi Tan, Lu Chen, Srinivas Reddy
Alla, Hoang Tran, Lei Du-Cuny, Longzhang Tian, Sharangdhar Phatak, and Nathan
Ihle. I owe great acknowledgement to my advisory committee, for their valuable
inputs and insights into this thesis. I could not have done it without your support. I
also thank all the members in Hui-Kuan Lin’s lab, especially Lori Chan, and the
members of Dr. Naoto Ueno’s lab; all are great researchers for their dedicated
contributions to the collaborative efforts in their experimental validations.
I also acknowledge the Texas Advanced Computing Center (TACC) at The
University of Texas at Austin for providing HPC resources that have contributed to
the research results. URL: http://www.tacc.utexas.edu

iv

Abstract
Discovery and effects of pharmacological inhibition of the E3 ligase Skp2 by
small molecule protein-protein interaction disruptors
By John Kenneth Morrow, M.S.
Advisor: Shuxing Zhang, Ph.D.

Skp2 (S-phase kinase-associated protein 2), one component of the SCF E3
ubiquitin ligase complex, directly interacts with Skp1 and indirectly associates with
Cullin1 and Rbx1 to bridge the E2 conjugating enzyme with its protein substrate to
execute its E3 ligase activity. Skp2 is an Fbox protein (due to it containing an Fbox
domain) and it is the rate-limiting component of the SCF complex. Skp2 targets
several cell-cycle regulatory proteins for ubiquitination and degradation; most notable
and significant for cancer are the cyclin-dependent kinase inhibitor, p27. Skp2 is an
oncogene and studies have shown that over-expression of Skp2 leads to increased
degradation of p27 and increased proliferation in several tumor types. Additionally,
Skp2 is over-expressed in multiple human cancers. Clearly, Skp2 represents an
attractive target for attenuating p27 ubiquitination and subsequent cell cycle
progression. However, Skp2 does not have an easily identifiable and druggable
“pocket” on which small molecules can bind; it interacts with Skp1 through the Fbox
domain and binds to an accessory protein called Cks1 to bind to p27. Despite this
hurdle, in this study, two selective small molecule inhibitors of the Skp2 SCF
complex were discovered via an in silico screen that disrupt two places: the
Skp1/Skp2 interaction site and the p27 binding site via targeting hot-spot residues.
v

The Skp1/Skp2 inhibitor disruption resulted in restoring p27 levels in the nucleus and
blocks cancer progression and cancer stem cell traits. Additionally, the inhibitors
phenocopy the effects of genetic Skp2 deficiency. Two specific residues on Skp2
were predicted to bind to this Skp1/Skp2 inhibitor: Trp97 and Asp98. When these
residues were mutated to alanine, the inhibitor lost its ability to bind to Skp2. To
investigate the flexibility and understand the conformational change upon inhibitor
binding and dynamics of the SCF complex, molecular dynamics simulations,
homology models, and structural analysis was carried out on the complex with and
without the inhibitors. These simulations showed that the contributions of the Nterminal tail region of Skp2 does not contribute directly to the binding of these
inhibitors; but its conformation is important in the context of the other members of the
SCF complex. Further dynamics analysis validated the mutagenesis results, showing
that the two Skp2 mutants (Trp97Ala, Asp98Ala) that retained Skp1 binding but
blocked inhibitor binding were stable, whereas the mutant that was unable to retain
Skp1 binding (Trp127Ala) showed destabilization in the Fbox domain. Finally, active
recruitment events after post-translational modifications are shown to be possible by
the interaction of phosphorylated Ser256 on Skp2 with Lys104 loop region on Cul1
The model shows that this is due to the significant flexibility in the F-box domain of
Skp2, making this interaction very likely. These results show that Skp2 is a promising
target on which protein-protein interaction disruptors can be designed, and
consideration of the dynamics of protein complexes is required to understand ligand
binding.
vi
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Chapter 1: Introduction
1.1 Targeting Protein-Protein Interactions to Expand the Drug-Target Space
1.1.1 Current state of Small Molecule Cancer Therapies
Despite a reported spending of $50 billion on research in the pharmaceutical
industry into small molecule therapeutics (reported in 2006), there is a surprising lack
of information on the known universe on which these therapeutics act upon. It has
been proposed in 2006 that the consensus number of drug targets for all classes of
therapies that have been FDA approved numbers only 324 (1). This estimate is rather
liberal when compared to other studies that use slightly different metrics and at a
higher but still modest count of 667 (2). When one breaks down the approved drugs
based on the target type, the overwhelming majority of them target very few major
classes: G-protein coupled receptors (GPCRs), nuclear receptors, ion channels or
enzymes (most prominent of the enzyme category are the kinases) (1, 3) (Figure 1.
Distribution of Approved drugs sorted by target type. Enzymes and GPCRs make up
over 2/3 of all targets.. More recent and comprehensive studies in the last year place

1

the human-genome derived practical target count pathway analysis that put the
number at 273 (4), or even 218 (3).

Enzymes - 47%
GPCRs - 30%
Ion Channels 7%
Nuclear Receptors and Transporters - 8%
Other Receptors - 4%
Integrins - 1%
DNA - 1%
Micellaneous - 2%
Figure 1. Distribution of Approved drugs sorted by target type. Enzymes and GPCRs
make up over 2/3 of all targets.
The breakdown of the ChEMBL database conducted as of writing shows that
out of 7,610 total targets, 3983 or 52% are in the “enzyme” category (5). This
paradigm follows the classic drug-target model of considering a target druggable by
targeting the active-site of the protein and blocking natural ligands of these
receptors/enzymes. This becomes problematic when one considers that the nonenzyme classification of proteins expressed in the proteome make up the majority of
proteins involved in signaling pathways, transport, transcription, translation and other
2

vital cellular functions. Clearly then the state of small molecules remains very
narrowly focused on archetypes and models that can be argued as outdated especially
when one considers that many diseases, most notably cancer, remain best described as
a disease “at best, minimally controlled by modern medicine” (6).

1.1.2 PPIs and Their Potential as a Therapeutic Target
The inherent complexity of cancer (and other diseases that have multiple
pathways involved in their phenotype and have poor prognoses) leads us to the
conclusion that the paradigm of “one drug, for one target, for one disease” (also
sometimes referred to as “low-hanging fruit” is not capable of reducing the disease
burden. One must expand the drug-target space and consider unconventional target
types.
To expand this drug-target space and take into account the functions of proteins
in their relevant pathways, it is critical to consider that most cellular proteins do not act
as isolated units; they often form complexes with other proteins (7). Formation of these
protein complexes require specific interactions that become the foundation for almost
all biological processes, especially signal transduction. The complexity of these
protein-protein interactions (PPIs) is what primarily provides them with their diversity
in functions. From this complexity, distinctions can be made in the shape, size and
surface complementarity of protein-protein interactions (8-12). These interactions can
be described as locally optimized, with the clustered, networked, densely packed
residues contributing mainly and cooperatively to the stability of the complex (13). The
3

sites by which proteins interact with their partners are formed by surfaces with adequate
electrostatic complementarity and shape (14-17). Other major factors that influence
protein-protein interactions are hydrophobicity (9, 18) and electrostatic interactions
(16), and flexibility (14-16). While interfaces with an area as small as 1150-1200 Å2
have been described in low-stability and short-lived complexes, “standard-size”
interfaces (19) are roughly 1600 Å2 (+/- 400 Å2) and involve only small changes in
conformation (12) and approximately 750-1500 Å2 of the surface area buried in each
protein (20). The “large” interfaces bury 2000-4660 Å2 and occur mostly between Gprotein and other components of signal transducers, and between proteases and one
class of their inhibitors (17, 19). Understanding the connection between structure and
function of molecular systems can be achieved through examination of the proteinprotein associations, and enables the characterization of their energetic properties (21,
22). When one considers that there are over 45,000 protein-protein pairs in yeasts, it
should become apparent that the number of potential, druggable targets in humans is
enormous (23).
Cellular dysfunctions from faulty protein-protein interactions are the underlying
cause of a variety of diseases, including cancer and neurological disorders (24, 25).
Despite the critical importance and relative abundance of protein-protein interactions,
very few small-molecule PPI inhibitors have made the difficult transition from hits to
marketed drugs. While peptide-based inhibitors derived from 5-50 amino acids of a
single member of an interacting protein pair are easy to construct, conversion of these
peptides to “drug-like” molecules has proved to be the biggest hurdle (26, 27). One
4

significant part of this problem is the nature of the PPIs; classic protein inhibitors
primarily target well-defined grooves and pockets (28, 29), whereas PPIs are usually
large and relatively planar surfaces that were originally considered not conducive to
druggability by “drug-like” molecules (16, 30). Advancements in two areas: the
understanding of the physical nature of PPIs as well as the increasing diversity and
quality of small, lead-like compounds have allowed PPIs into the realm of valid targets,
thereby greatly expanding the available target space for a plethora of diseases (31, 32).

1.2 Hot spots as a Basis for Drug Discovery Efforts
Used with explicit permission from Bentham Science Publishers in the article:
Current Pharmaceutical Design. 2012;18(9):1255-65.

1.2.1 Introduction to hot spots
It has been well established that for all proteins, the energy distribution is not
uniform across a given protein-protein interaction; that a small subset of residues will
have a more significant contribution to the binding free energy than other residues (13,
33-40). Clackson and Wells’ pioneering study of the binding of human growth hormone
to its receptor discovered these important residues and coined the term ‘hot spots’ (33).
Later work revealed that hot spots occupy only a fraction of the larger interface area
(34), and proclaimed a more precise definition of a hot spot as a residue whose mutation
to alanine results in a decrease of at least 2.0 kcal/mol in binding free energy
(ΔΔGbinding) (41). Binding free energy, or ΔΔG, is defined as ΔGmut – ΔGwt, where ΔGwt
5

and ΔGmut are the binding free energies upon complex formation of the wild-type and
alanine-mutated proteins, respectively. It has been calculated that 9.5% of interfacial
residues are hot spots (42).
The composition of hot spots is distinctive and not random, with tryptophan
(21%), arginine (13.3%), and tyrosine (12.3%) being the only three fundamental amino
acids having more than 10% frequency (34, 43). The complex formed by human growth
hormone and its receptor is shown with its dominating tryptophan residues (Figure 2).
Out of the 29 interfacial residues in this complex, only four hot spots have ΔΔGbinding
greater than 4.5kcal/mol, and two of them are tryptophan. Tryptophan’s unique function
can be partially explained by its large and aromatic π-interactive nature (44) as well as
its large hydrophobic surface and protective effects from water (45). When the bulky
tryptophan residue is mutated to alanine, the difference in size generates a large cavity
that creates a highly complex destabilization (34).

6

Figure 2. Example of typical hot spot residues of human growth hormone (green
cartoon) and its receptor (blue sticks) (PDB Code 1a22). Three of the four hot spot
residues of the receptor are represented in sticks, hydrogen bonds are shown in dashes.
This result was displayed using PyMOL (46).
Consideration of the structural aspects of hot spots (47, 48) reveals that they are
cooperative and structurally conserved (13, 36, 49, 50). This structural conservation is
also apparent when examining the rate of mutation of surface residues; protein
interfaces (51) and functional sites (52) mutate at a relatively slower rate when
compared to other surface residues. Mutations of the interactions between proteins may
occur largely by coevolution, where substitutions in one protein trigger reciprocal
changes in the other protein (51). Numerous studies of protein-protein interfaces have
revealed the presence of hot spots where binding affinity and specificity can be resolved
by an epitope that is consisting of only a small portion of interfacial residues (34, 35,
53-55). Clearly, the structural conservation of hot spots and their correlating binding
affinity make them attractive drug targets for small molecule inhibition. It is not
7

surprising then, that hot spots have been considered in the design of small molecule
inhibitors of unwanted protein-protein interactions, and several potential drugs show
great promise in targeting hot spots (20, 25, 42, 56-63).

1.2.2 Hot spots as potential drug targets
Hot spots can facilitate drug design in two ways. First, the binding site can be
predicted by the presence of hot spots, and this binding site can be considered a starting
point to perform docking and/or screening of ligands (64). Second, rigid docking could
exploit the relatively less flexible hot spots, and improvements in protein docking
would be achieved by choosing dominant conformation of the hot spot side chains
resulting from molecular dynamics (MD) simulations rather than the unbound X-ray
conformation (65, 66). Initial studies have shown that hot spots have physico-chemical
properties that may be predictive (42, 53), and this prediction goes a long way to
decipher the functional mechanism of proteins. From the mechanisms, valuable
information can be used for a wide range of purposes: mutant proteins can be designed
that will validate the interactions, drugs can be developed that target the protein-protein
interactions, and molecular recognition can be expanded to help us understand complex
signaling pathways.
Successful identification of hot spots involved in protein interfaces is crucial in
determining potential active sites, and the corresponding druggability of a protein
target. It is only after the completion of this step that rational, structural based drug
design can begin. Systematic mutagenesis of protein-protein interactions has yielded a
8

wealth of information on the hot spots themselves, but there are significant inroads that
can be made as to the general nature of these hot spots. Unfortunately, no general
patterns of shape, charge or hydrophobicity exist that can be used to predict which
residues form hot spots (12, 16). Additionally, residue conservation is rarely sufficient
for accurate prediction of protein interfaces (50). Further potential pitfalls become
apparent when considering the inherent plasticity and expansive diversity of PPIs.
Despite these challenges, the increasing use of computational methods holds
high potential to provide accurate analysis in prediction of hot spots at a fraction of the
time and cost for conventional, experimental techniques. Advancement in both
hardware processing power as well as software predictive models will increase the
speed and the accuracy of hot spot predictions. The increasing rate of both
crystallographically resolved protein-protein complexes as well as experimental alanine
mutagenesis studies will provide a more comprehensive dataset from which to further
increase the accuracy of computational prediction of hot spots. Composite approaches
that incorporate initial computational predictions, and are then validated against
experimental means provide the most comprehensive understanding of the nature of hot
spots. These validations will vastly improve the predictive power of in silico techniques
by continually evolving from the increasing pool of data from which they are built upon.

1.2.3 Current Experimental Methods to predict hot spots
Experimental identification of hot spot residues is primarily performed by
alanine scanning. This process involves mutation of a residue of interest to alanine, and
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recording the resulting binding energy changes. If this mutation results in a marked
drop in the binding constant (typically tenfold or higher), the residue is considered a
hot spot (53). Substitution with alanine removes all atoms in the side chain past the βcarbon. Alanine is used because of its relatively inert methyl functional group without
contributing additional flexibility (67-69). Mutation to glycine would also remove the
side chain, but is not used since it can introduce unwanted conformational flexibility in
the protein backbone (70).
In the context of protein folding, a mutation on a hot spot residue can be considered to
destabilize the bound ensemble state relative to the unbound one (71, 72). It follows
then that alanine scanning determines the specific contribution of residues to the
ensemble’s stability, and resulting protein function.
If we are to consider the plasticity of protein interfaces, alanine scanning
mutations affect free energy surfaces that can lead to differential effects of the bound,
unbound state, or both (Figure 3). It becomes advisable then to interpret both the
structure and energetic properties of each ensemble to rather than a specific residue
interactions (53). Initially, alanine scanning was applied towards human growth
hormone and the growth hormone binding protein (33), and this technique has proved
invaluable in PPI analysis and hot spot detection (12, 34, 39, 53, 61). The resulting data
from alanine scanning can be deposited in the Alanine Scanning Energetics Database
(ASEdb), and verified experimental hot spots from the literature are found in the
Binding Interface Database (BID) (41, 73). These repositories, while useful, have two
drawbacks. First, hot spot information from experimental studies is limited to very few
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complexes. Secondly, it is not recommended to interpret this data to specific residue
interactions (53).

Figure 3. Mutations from alanine scanning can affect free energies of bound and
unbound states. Mutant A is an ideal result where only the complex is destabilized, and
the binding free energy with respect to the wildtype (ΔΔG) can be attributed to specific
changes in the PPI contacts. Mutant C affects both states simultaneously. The measured
binding free energy difference from B and C mutants must be interpreted cautiously.
(Figure adapted from (53): “Unraveling hot spots in binding interfaces: progress and
challenges”, used with explicit permission from Current Opinion in Structural Biology).
Experimental mutagenesis of target proteins for elucidation of hot spots is not
applicable on a large scale since individual mutants must be purified and analyzed
separately (53). Systematic analysis requires each alanine-mutated protein to be
constructed, placed in an expression system sometimes refolded, then the resulting
protein activity is assessed in an in vitro assay (70). While techniques such as
reflectometric interference spectroscopy (74) and “shotgun scanning” (75) have
alleviated some of the labor involved, experimental hot spot analysis is still very time
consuming and expensive. The theoretical and computational prediction of hot spots
has become one of the most attractive and challenging topics in biochemistry,
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biophysics, and bioinformatics, and each of these disciplines offer unique strategies to
confront this challenge. Next, we will outline the methods and tools available for
computational hot spot prediction (Table 1).
Hotspot
Properties Used

Availability

Technique

Tool &

Computational

Reference

prediction

FoldX

Energy-based

(76)
Server

alanine scanning
Computational

Robetta

Energy-based

Server

(77)
alanine scanning

Energy, structurePP_Site
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(78)
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Probe based rigid
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with fast Fourier

(79, 80)

Server
transform
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PCRPi,

Energy, structure,
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Bayesian
(81, 82)

PCRPi-W

evolutionary

Guhary &

H-bonding,

Chakrabarti

Server

Network

Tool
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(83)

interface location
ASA, various

KFC2

Support Vector
Server

structural features

Machine (SVM)

Structure,
MINERVA

(84)

Descision Tree,
Tool

sequence,

(85)
SVM
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molecular
interaction
SVM (Residue
HSPred

Energy-based

Tool

(86, 87)
specific)

Rajamani

Side chain ΔASA

Molecular
Tool

(65)
Dynamics

Structural,
Higa & Tozzi

Tool

SVM

(88)

evolutionary
Normalized
Grosdidier &

Energy-based

Recio

(Docking)

Tool

interface

(89)

propensity
Conservation,
HotPoint &

Server &

Empirical

Database

formula

accessibility,
HotSprint

(46, 90)

residue propensity
Table 1. Summary of Hot Spot Prediction Methods

1.2.4 Current Computational Methods to predict hot spots

1.2.4.1 Energy-based Computational Methods
Computational alanine scanning estimates the energetic contribution of each
residue to the total binding energy via virtual alanine scanning. The process for
computational alanine scanning is briefly described as follows: Using a side chain
repacking algorithm, mutation of each interface residue to alanine is performed. Then,
a numeric energy function is used to evaluate the bound and unbound states of the
original and mutant proteins. Finally, the change in the binding energy (ΔΔG) of each
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mutation is calculated thermodynamically. This approach requires the complex
structure as input and is best for providing an accurate estimation of free energy charges
(91).
One such algorithm is FOLDEF, available as the FoldX web server. It was
developed by Guerois et al., and was used to predict the energetic effect of mutations
on protein complexes. FOLDEF was built on the FoldX complex energy function,
which systematically truncates side chains between two proteins (or protein-peptide) to
alanine, then calculates change in the binding energy after relaxation (76). The complex
energy function contains terms for: implicit and explicit desolvation, van der Walls
forces, hydrogen bonding, Coulombic electrostatics, changes in entropy, and dipole
interactions. FOLDEF was trained on a database of 339 mutants and gave a global
correlation of 0.83 and a standard deviation of 0.81kcal/mol when tested on a database
of 1,030 mutants. FoldX predictions have a linear correlation with experimental binding
energies, and the standard deviation of predictions from a linear regression of the data
is 0.88 kcal/mol (92).
Similarly, Kortemme and Baker used a simple physical model (named Robetta)
that includes various parameters including: Lennard Jones interactions, solvation
interactions, packing interactions, implicit solvation and hydrogen bonding to calculate
free energy (77). Similar to FoldX, the Robetta energy function was parameterized from
protein stability data. Robetta mutates side chains to alanine and locally repacks the
structure within 5Å of the mutant residue, while keeping the rest of the protein
unchanged. The predicted changes in binding energies form the basis for hot spot
14

predictions (93). When tested on a database of 743 mutations in the interface of each
protein (from the ASEdb), Robetta was able to correctly predict 79% of hot spot
residues with a 1.0 kcal/mol cutoff, and an average error of 1.06 kcal/mol (93, 94). The
implicit solvation model has two potential errors: Robetta cannot identify hot spots that
are involved in water-mediated hydrogen bonds, and when waters can compensate for
a mutation, it will incorrectly predict mutations as hot spots.
Gao et al. developed a structure-based method, called PP_SITE, based only on
three properties: H-Bond, hydrophobic and van der Walls interactions. PP_SITE is
developed based on POCKET, which is a module of the multi-purpose program
LigBuilder (95). PP_SITE creates a box with regularly spaced grids to cover interfacial
residues and uses probes for each structural property to screen those grids. The probes
include a positively charged sp3 nitrogen (ammonium cation), a negatively charged sp2
oxygen (as in a carboxyl group), and a neutral sp3 carbon atom (methane). For each
grid, the scores are calculated and a grid label is assigned to it. This method then offers
the ability to analyze the decomposition of the contributions of regions in the predicted
hot spots, enabling comprehensive exploration of the properties of the protein-protein
interface. PP_SITE was tested on 13 complexes with 250 alanine mutations on
interfacial residues. For the 75 hot spot residues in this set, 66 were predicted correctly,
giving an 88% success rate (ΔΔG > 1.5 kcal/mol) (78).
FTMap (79) is a recent approach that uses docking results of small organic
probes to discover hot spots. It was originally conceived as a computational equivalent
of the experimental multiple solvent crystal structures (MSCS) technique, where a
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target protein is co-crystallized in the presence of a diverse set of organic solvent probe
molecules. It has been shown that molecular probe distribution on the protein surface
allows for discovery and characterization of potential ligand interaction sites (96). The
FTMap algorithm samples billions of positions from 16 small molecule probes (with
varying hydrophobicity and hydrogen-bonding capacity) globally across the total
protein surface using a fast Fourier transform correlation approach. The poses are
evaluated with an empirical scoring function that includes van der Waals terms,
electrostatic interaction energy, a cavity term to represent the effect of nonpolar
enclosures, and a structure-based pair-wise interaction potential. The 2000 most
favorable docked conformations are energetically minimized and clustered. The lowest
energy clusters from different and overlapping probe types are clustered again into
consensus sites; the largest consensus site is generally located at the most important
sub-site of the protein binding site. FTMap is available as a publically-available server,
where only the PDB file or a PDB code of the protein is required. The output shows the
six lowest energy cluster representatives as well as the number of non-bonded and
hydrogen bonds between the probes and each residue in the protein (Figure 4).
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Figure 4. FTMap results for carbonic anhydrase I (PDB 2CAB) displayed in PyMOL.
The pocket nearest to the center contains 19 docked probes, and is the binding site for
drugs acetazolamide, methazolamide, and foscarnet

Another recent method called PCRPi (Presaging Critical Residues in Protein
interfaces) is based on the integration of three main sources: energetic, structural, and
evolutionary determinants by using Bayesian networks to unify them into a common
probabilistic framework (81). Specifically, the attributes are: interaction engagement
index, topographical index, four separate conservation indexes (ANCCON,
ANC3DCON, CON, and 3DCON), and the BE index. The BE index is an in silico
alanine scan using FoldX (76). This method has been developed as a web server (called
PCRPi-W) where users can enter a PDB code or upload a complex, as well as select the
type of Bayesian network architecture (naïve or expert) (82). Two different types of
training sets are available for users: Ab+, which contains entire dataset of 636 interface
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residues, including antigen-antibody complexes, and Ab-, which does not include these
antigen-antibody complexes. Using a BID dataset derived in Tuncbag et al. (97), the
PCRPi-W method recorded a precision of 0.79 and recall of 0.64 when compared in a
head-to-head comparison with other computational methods (82). Also of note, the
PCRPi-DB is the result of annotating and archiving the entire Protein DataBank (98)
using PCRPi (99).
Finally, Guharoy and Chakrabarti used only the two criteria: hydrogen bonding
across the interface, and location in the interface core to predict more than 80% of hot
spots with experimental contribution of core residues to the energy of binding (ΔΔG >
2 kcal/mol) (83). An experimental database of 462 mutants from 28 interfaces was used,
out of which 143 form hydrogen bonds. The average unsigned error (calculated as |
ΔΔGcalc - ΔΔGexp|) for all mutations was 1.04 kcal/mol. This technique is
computationally inexpensive due to its small number of parameters, and is hence
potentially applicable across a large set of complexes. One limitation of this technique
is that coupling and indirect effects cannot be considered explicitly.

1.2.4.2 Molecular Dynamics-Based Methods
These types of methods are also energy-based, but use more intensive molecular
dynamics computations to provide an atomic level of hot spot prediction. Therefore we
grouped them separately. One particular study using MD techniques looked at anchor
residues, which are residues that have limited mobility and strongly correlate with
conserved hot spot residues (100). The study of anchor residues was conducted by
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Rajamani et al. on 11 different proteins and concluded that these residues have side
chains that experience the largest decrease in solvent-accessible surface area (>100 Å2)
when in a complex (65). From their analysis of 39 complexes, they concluded that
anchor residues have high structural conservation across different homologs. They also
found that the anchor residue (primarily from the smaller of the two proteins) binds to
a structurally constrained binding groove of the other protein that stabilizes the bound
intermediate state, and the larger the buried surface area of the main anchor residue, the
fewer secondary anchors are required for complex formation (65). This work was based
on another group’s nanosecond explicit solvent MD simulations of three complexes and
the observation that key side chains frequently display the rotamer conformations of
the complex before any receptor-ligand interaction (101).
Huo et al. applied a MM-PBSA (molecular mechanics-Poisson-Boltzmann
surface area) approach to the human growth hormone-receptor complex (hGHpb).
Here, protein-protein interfaces are probed with explicit molecular mechanical
energies, continuum implicit solvation free energies, and approximations of vibrational
entropy changes. All of these terms are then averaged over each conformation provided
by the MD simulation. Using free energy calculations of snapshots equally spaced along
a single dynamical trajectory, they were able to predict the experimental ΔΔG of
binding with an average error of ±1kcal/mol for the alanine mutations of hydrophobic
and polar/charged residues without buried salt bridges (102). The full structural and
energetic consequences of a mutation of a bound and unbound state can be adequately
described when the proper thermodynamic cycle is employed (102). This
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comprehensive analysis requires repeated sampling of the mutant in both bound and
unbound forms, which is computationally expensive when compared to other methods,
especially on a large scale. To circumvent this potential computational roadblock,
approximations to generate the mutant ensembles can be used which simulate first the
un-mutated protein, then are post-processed to introduce mutations to alanine (64, 103).

1.2.4.3 Machine Learning-based Methods
The third method uses learning based methods (commonly called machine
learning, or ML). This method is very novel, considers a diverse series of factors, and
will be used in future drug discovery efforts. The KFC (Knowledge-based FADE and
Contacts) uses a rule-based model created by a machine learning algorithm to elucidate
structural patterns that are indicative of hot spots. The KFC model is actually a
combination of two learned decision tree models: K-FADE uses the residue size and
radial distribution of shape specificity and interface points calculated by Fast Atomic
Density Evaluation (FADE) (104), and K-CON uses the residue’s intermolecular
atomic contacts, hydrogen bonds, interface points, and chemical types (105). These
structural features return a binary answer as to whether a residue is a hot spot or not,
and a confidence score with each prediction. Alone KFC predicted 58% of alanine
scanning hot spots with precision of 49% and recall of 58% when a hot spot is
associated with ΔΔG > 2kcal/mol. When KFC was combined with Robetta’s
computational alanine scanning technique described previously, (the combined model
called KFC+Robetta-Ala, or KFCA) (93), the predictive accuracy jumps to 72%. The
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KFCA analysis was applied to two complexes: the calmodulin (CaM)/smooth muscle
myosin light chain kinase (smMLCK) and to the bone morphogenetic protein-2 (BMP2)/BMP receptor-type I (BMPR-IA) complex. Both complexes had strong correlation
between KFC hot spot predictions and experimental mutations, and in the case of
BMP2, KFC was able to highlight a region where alanine mutation of two key residues
(Phe49 and Pro50) are more disruptive than the sum of the individual mutations (106).
A more recent study also used the KFC method in the study of the interaction of the
antibody, called 19D9D6, and the hepatitis C virus (HCV). Comparison of MD
simulation results matched three residues that were predicted as hot spots in KFC that
are important for the interaction between the virus and antibody (107). The KFC
method is now available via an interactive, public web server, where users can submit
complexes (via uploaded file, or providing the PDB code) and view results for each job,
as well as upload scores from Robetta’s alanine scanning, ConSurf sequence
conservation, or experimental data (105).
The KFC method has been recently improved, with two new models trained
using a support vector machine (SVM) (108): KFC2a and KFC2b. KFC2a is composed
of eight features primarily related to solvent accessibility, interface position, packing
density, and local plasticity. This KFC2a model showed a true positive rate of 0.85,
outperforming HotPoint, KFC, Robetta, and FOLDEF, despite having a slightly higher
false positive rate than the other models. KFC2b uses seven features (two of which are
found in KFC2a), and boasts a higher specificity (84).
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Cho et al. applied a SVM that initially incorporates 54 multifaceted features
from structure, sequence, and molecular interaction. The model is named MINERVA,
an acronym of MINE, Residue VAlue. From these 54 features, decision tree selection
is performed to identify the best feature subset. Atomic packing density, relative surface
area burial and weighted hydrophobicity are the top three features for picking hot spots
that were selected from the decision tree, with the weighted atomic packing density
displaying the highest effectiveness (85). Previous hot spot and conservation analysis
has shown that local packing density around conserved residues and hot spots is higher
than anticipated, and a good correlation exists between local packing density and
experimental ΔΔG (109). MINERVA displays better sensitivity, specificity, precision
and F1 score than Robetta, FOLDEF, and KFC when tested on two different training
sets; the best performance occurred when the model was trained on the 2 kcal/mol set
rather than the 1 kcal/mol set (85). Their work also revealed that residue conservation
is not ideal for correctly identifying hot spots, and that hot spots are closely related to
π- π interactions.
Another group that has successfully used SVM is Lise et al., who previously
described a hybrid method in which energy terms are used as input features of a SVM
classifier and is called HSPred (86). Their method considers basic energy terms (van
der Waals, H-bond, electrostatic and desolvation potentials, hydrogen bonds, and
Coulomb electrostatics) calculated from the complex structure. In a later study, this
model was improved by 10% in overall precision and recall by creating separate SVM
classifier predictions specifically optimized for arginine or glutamic acid residues, as
22

these amino acid types did not perform well in the original model (87). The method is
also available as a web server and is free to non-commercial users (87).
A set of 43 structural and evolutionary parameters were used with an SVM
classifier in the work by Higa and Tozzi. These parameters can be grouped into the
following types: amino acid type, evolutionary profile, conservation score, surface area,
solvation energy, and geometry (88). When using the dataset compiled by Darnell et
al.(106), this method had a performance of 60.4% (measured by F-Measure) that
corresponded to a recall of 78.1% and a precision of 49.5% (88). This work is
significant in that it does not require the complex; it can be used with only knowledge
of the monomer. As a result, this method can be used when the interface region is
unknown, and can prove useful for discovery of novel protein interfaces.
Another method that does not require prior knowledge of the complex structure
is the work from Grosdidier and Recio, whereby the analysis of rigid-body docking
ensembles provides normalized interface propensity (NIP) values. This NIP parameter
is obtained from rigid-body docking simulations and calculates the propensity of a
given residue to be located at the interface. It includes electrostatics and desolvation
scoring in its calculations for predictions (89). The NIP method was developed from
their previous findings that highly populated low-energy regions consistently
corresponded to proven binding sites (110). Their method has up to a 80% positive
predictive value, but it is not exhaustive and will miss hot spots that are not directly
involved in the interface or arise from highly specific interactions (89).
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While machine learning methods hold great promise, it is worth mentioning that
simple empirical models can provide better predictive power. Tuncbag et al. presented
an empirical model based on conservation, accessible surface area (ASA), and
knowledge-based pairwise residue potentials of the interface residues This model
provides 70% accuracy, higher than machine learning based methods when using 150
residues from ASEdb as the training set (97). Later, this method was incorporated into
a web server, called HotPoint, where users can upload a protein complex and quickly
visualize results (46). The relative residue solvent accessibilities are calculated in the
complex and monomer states, and the solvent mediated potentials are taken from
Keskin et al (111). If the following two qualifications for a residue are met: the relative
ASA in complex is less than or equal to 20%, and the total pair potential is greater or
equal to 18.0, then that residue is labeled a hot spot (46). Change of solvent accessible
surface area (ΔASA) upon the formation of a complex is strongly related to the
solvation energy, which has been shown previously to be one of the most significant
factors involved in protein-protein binding (112). This technique was also used to
correctly identify the hot spots on Mdm2. Another database named HotSprint was
developed by the same group. It was the first database to exploit sequence conservation
and incorporates solvent accessibility of residues. This method gives an accuracy of
76% that performs better than several machine-learning based methods (90).
1.3 The Ubiquitination Pathway
Sections reproduced from Future Medicinal Chemistry. (2015) 7(17), 23332350 with implicit permission of Future Science Group
24

1.3.1 Introduction
Ubiquitination, a step in the non-lysosomal degradation of proteins, is a
crucial post-translational modification in eukaryotic organisms. Rapid and timely
degradation of transcriptional regulators and other proteins by the ubiquitinproteasome system (UPS) regulates a wide variety of cellular processes(113).
Ubiquitination involves covalent attachment of ubiquitin, a small 8-kDa protein, to a
substrate and results in recognition and shuttling of the substrate to the 26S
proteasome complex for degradation (114). It is important to note that the
ubiquitination process combined with the proteasome complex step is also referred to
as the ubiquitin-proteasome system (UPS) or ubiquitin proteasome pathway (UPP).
The ubiquitination process is tightly controlled by three families of enzymes:
ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and finally
ubiquitin-protein enzymes (E3s). There exists two E1 enzymes with ubiquitinactivating capability : UBA1 being the primary E1 and the recently discovered UBA6
with unclear functions and uncharacterized regulations (115, 116) In contrast to the
small number of E1s, there are approximately 40 E2s (117, 118) and 500-1,000
human E3 ligases, providing both specificity and versatility (119). The three steps of
the ubiquitination process (Figure 5) have been reviewed previously (120, 121).

25

Figure 5. General structural outline of ubiquitin/proteasome pathway. E1s (Blue) are
activated by ATP and bind to ubiquitin (orange). They then transfer ubiquitin to E2
(blue) and the E3 enzyme transfers ubiquitin to the substrate, which is then shuttled to
the proteasome for degradation.
Briefly, the activation step requires binding of both ATP and ubiquitin and
links the α-carboxyl group of the C-terminal glycine residue of ubiquitin to a cysteine
residue on E1, and a thioester linkage is formed between the ubiquitin and E1. Then
the E2 binds to both activated ubiquitin and the E1 enzyme and thus transfers the
ubiquitin from E1 to the active site cysteine of the E2 via a trans(thio)esterification
reaction. Finally, the E3 catalyzes the linking of ubiquitin to a lysine residue on the
substrate. Repetitions of these sequential steps results in long chains of ubiquitin
(polyubiquitin) on the protein to be degraded, and the specific lysine residue on
ubiquitin used for linking (e.g., K48, K63, etc.) results in different topologies (122).
Ubiquitination was originally described as a mechanism by which cells dispose of
short-lived, damaged, or abnormal proteins, but more recent studies have revealed that
it also plays a significant role in post translational modification. Ubiquitination can
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result in the addition of a single ubiquitin moiety, called monoubiquitination, rather
than polyubiquitination. Generally, polyubiquitination reactions are formed on the
K48 residue, and this process tags substrates for proteasomal degradation and
recycling (123). On the other hand, the K63-linked non-proteolytic ubiquitination
spares proteins from degradation and regulates localization and activity of multiple
kinases and pathways, such as PKB/Akt, TAK1, IKKγ/NEMO, TNFR, IRAK1,
MLK3, IGF-1R, T cell receptor (TCR), NOD-like receptor (NLR), and RIG-I-like
receptor pathways. This type of ubiquitination can cooperate with other linkage types
to achieve the physiologically required output of a signaling pathway (122, 124, 125)
and therefore has been crucially implicated in diverse biological processes including
signal transduction, transcriptional regulation, growth response, innate immune
response, and DNA repair and replication (124-126).
Mitotic cell cycle progression through each stage is tightly controlled by
cyclin-dependent kinases (CDKs), and their relative interactions with members of the
cyclin and CDK inhibitor (CKIs) families. The relative amounts of these signal
factors fluctuate within and between each stage of the cell cycle occurs via the result
of periodic proteolysis(127); the ubiquitin-proteasome scheme is responsible for the
degradation of these mitotic regulatory proteins, which results in the control of their
intracellular concentrations(128, 129).
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1.3.2 Ubiquitination in Cancer
Ubiquitination can affect cancer development and progression in many ways.
Both tumor suppressing and promoting pathways have elements that are tightly
regulated by the process. One fundamental aspect of cancer is the deregulation of the
cell cycle and checkpoint control (127). which is highly regulated through constant
synthesis coupled to a particular timeframe of specific proteolysis of cyclins, cyclindependent kinases (CDKs) as well as CDK inhibitors (CKIs) executed by the UPS
(130). Other cell cycle regulatory proteins that may contribute to cancer progression
include cyclin E, p57, p130, FoxO1, c-Myc and E2F1 (131, 132).
Another well-known example is the E3 ligase MDM2 which bind to the tumor
suppressor protein p53 that is inactivated in more than 50% of human cancers. Also,
mutations and alterations in ubiquitin ligases are found in a wide variety of tumor
types and tremendously impact clinical outcomes (133-136).
In addition to the above proteolytic polyubiquitination, which may contribute
to cancer development, it is worth mentioning that monoubiquitination has unique
effects on cancer as well (125). Monoubiquitin can serve as a recruitment signal to
proteins that contain ubiquitin binding domains, and the functions of such nonproteolytic ubiquitination include, but not limited to: altered protein activity,
subcellular localization, enzyme activation, DNA repair, chromatin dynamics (124,
137-139), and transcriptional regulation(140, 141). These facts underscore the
importance of ubiquitination in tumorigenesis and the resulting interest as a clinical
target.
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1.3 Existing Small Molecules Targeting Ubiquitin/Proteasome Pathway
1.3.1 Targeting the Proteasome
The first therapeutic proteasome inhibitor tested in humans was bortezomib
(Velcade), which was first synthesized in 1995, entered clinical trials in 1998, and
approved by the FDA for use in multiple myeloma (MM) in 2003 (142) (Table 2).
The clinical antitumor activity of bortezomib is well established as both a single-use
agent and combination in the treatment of MM and other hematological malignancies.
Bortezomib also exhibits efficacy in non-small cell lung cancer and pancreatic cancer
(143, 144), and more recently it was expanded for use in patients with mantle cell
lymphoma (MCL). High affinity and specificity of binding of bortezomib is achieved
partly through the boron atom to the 26S proteasome’s catalytic site (145-147).
Consequently, proteasome inhibition alters the balance of all intracellular peptides,
increasing those that require cleavage at acidic and hydrophobic sites and causing side
effects such as neuropathy and autophagy in certain conditions (148-151). As is an
issue with many cancer therapeutics, resistance can develop quickly and this occurs
with bortezomib on average in about one year (140, 152, 153). Another notable
proteasome inhibitor approved recently by the FDA is carfilzomib (marketed under
the trade name Kyprolis), and is used for relapsed and refractory MM who have been
previously treated with bortezomib (154, 155). Carfilzomib is also approved for MM
and was derived from epoxomicin, a natural product that was shown to contain potent
anti-inflammatory activity and proteasome inhibition (156).
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Table 2. Selected compounds targeting elements of the ubiquitin–proteasome system
and their current status in the drug development pipeline.
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Other next generation proteasome inhibitors are in clinical trials and have the
potential to achieve a better therapeutic ratio and reduced probability of inherent and
acquired resistance. An example is the structurally and pharmacologically unique
marizomib (also called salinosporamide A) currently in Phase I trials (157). It is a
natural product produced from marine bacteria, and its mechanism of action is unique
in that it irreversibly and covalently modifies the active site threonine residues of the
20S proteasome (179, 180). Moreover, a Phase Ib clinical study of the combination of
marizomib with vorinostat has just completed but the results have not yet been posted
with non-small lung cancer patients (Clinical Trial NCT00667082).
Finally, two other reversible peptide boronic acid-based proteasome inhibitors
in different stages of development are CEP-18770 and MLN-9708 (181, 182). CEP18770 has been tested in Phase I trials for solid tumors and non-Hodgkin’s
lymphoma, and entered Phase II trials for relapsed and refractory MM by itself and in
combination with lenalidomide (a thalidomide derivative) and dexamethasone
(Clinical Trials NCT00572637, NCT01023880, and NCT01348919). It has shown in
vitro antiangiogenic activity and potently represses RANKL-induced
osteoclastogenesis, and is not cytotoxic to normal human epithelial cells and bone
marrow-derived stromal cells (159). MLN-9708 (also called Ixazomib) has shown
great promise and advanced to Phase III trials; it is also being considered in
combination with lenalidomide and dexamethasone (Clinical Trial NCT01564537). In
Phase II trials, while showing adverse side effects, it was generally well tolerated and
the majority of patients (58%) had a very good partial response or better (158).
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1.3.2 Targeting E2 Enzymes
While few therapies targeting the E2 enzymes are in development (relative to
proteasome and E3 inhibition), there are some recent examples worth mentioning that
are in preclinical stages (Table 1). Leucettamol A, which was isolated from the sea
sponge Leucetta aff. Microrhaphis, was shown to inhibit the Ubc13-Uev1A interaction,
blocking the E1-E2 complex formation (160). It was determined that, contrary to an
earlier assessment that this was a racemic compound, it is in fact a chiral and optically
active compound (161). Another marine sponge, Lissodendryx fibrosa was the source
for manadosterols A and B which inhibited the same Ubc13-Uev1A interaction with
higher potency than leucettamol A (183). CC0651 was found to allosterically inhibit
the E2 enzyme Cdc34 and cause accumulation of p27 by inserting itself into a cryptic
pocket distant from the catalytic site, causing displacement of secondary structural
elements (162). However, targeting the E2 is still lacking sufficient specificity
compared to E3 inhibitors as described in the following sections.

1.3.3 Targeting E3 Ligases
E3 ubiquitin ligases represent a diverse set of enzymes and provide the
specificity of the ubiquitination reaction, and have significant roles in many different
diseases, especially cancer. The E3 ligases are currently broadly classified into two
major families from their structural motifs: HECT-type (Homologous to the E6-AP
Carboxyl Terminus) and RING type (Really Interesting New Gene); RING domain
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ligases are the most common (184). There are also two RING-finger derivative
domains: U-box (UFD2-homology domain) and PHD (plant homeo domain) E3 types,
but RING-finger types are the largest groups of E3 ligases.
E3 elements in the UPS are considered to be primarily responsible for the
specific recognition of a large number of target proteins, acting as the substrate
recognition component of the UPS pathway (114). This specificity is crucial when
considering the prospect of designing drugs for the entire ubiquitination pathway, as
they can be designed to target specific substrates of the E3 ligase without affecting
other substrates. As a result, the E3 ubiquitin ligases are drug targets with the most
potential for cancer therapies as they have fewer targets and offer a higher specificity
of the system (185, 186). There are several notable E3 ligase targeting agents that are
worthy of mentioning, and there have been many recent developments that show
promising results in preclinical testing.

1.3.3.1 Thalidomide and its Derivatives
Thalidomide was originally developed as a sedative and an agent to cure
hyperemesis gravidarum in pregnant women, and became infamous for its limb
formation birth defects. Although banned after discovery of these effects in 1962, it
had off-label use for patients of erythema nodosum leprosum (ENL); it was this use
that led to clinical trials of its assessment and characterization of its
immunomodulatory effects. Its primary target has been identified to be cereblon
(CRBN), which forms an E3 ligase complex with damaged DNA binding protein 1
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(DDB1) and Cul4A that is important for limb development, and binding of
thalidomide to this complex appears to be the mechanism for the teratogenic effects in
embryonic development (163). Two optimized second-generation derivatives of
thalidomide, lenalidomide and pomalidomide (164, 165), are also used for MM by
targeting CRBN and modulate its specificity as a substrate receptor, not by inhibition,
rather by selective enhancement of the ubiquitination and degradation of Ikaros 1 and
3 (IKZF1 and IKZF3) zinc finger transcription factors (187). A crystal structure of
lenalidomide in complex with CBRN shows the binding mode and that it binds to the
substrate binding domain of CRBN and blocks ubiquitination (188-190).

1.3.3.2 MDM2/p53
The tumor suppressor protein p53 has been called the “guardian of the
genome” due to its critical role in inducing cell cycle arrest and apoptosis in response
to DNA damage. There exist over ten E3s associated with the regulation of p53, but
the one with the most unquestionable importance has been MDM2 (murine double
minute 2)(191). The p53-binding domain of MDM2 is at the N-terminus, and the
RING domain in the C-terminus acts as the ubiquitin ligase to promote rapid
degradation of p53 after its export from the nucleus (192-194). Inhibition of the
MDM2/p53 interaction has been achieved by the small molecule nutlins, which have
completed Phase I clinical trials and (166, 167). Nutlins are the general name given
to compounds based on a cis-imidazoline scaffold, and their derivatives offer better
activities but still retain elements of the core structure. Serdemetan was tested in a
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Phase I trial and showed good p53 induction, but cardiac construction effects were
observed (195-197). Nutlin-3a (a more promising agent) was optimized for better
pharmacological properties to become RG7112 (also known as RO5045337); it
stabilized p53 and activated the p53 pathway in cancer cells, and is being tested both
as a monotherapy and in combination and some Phase I trials are still ongoing
(NCT01677780) (168, 198). Nutlins and their derivatives are competitive inhibitors
and structural mimics of p53 (via Phe19, Trp23 and Leu26) (166). MDMX (murine
double minute X – also known as HDMX in humans, or also MDM4 or HDM4)
shares significant homology with MDM2 and is also a negative regulator of p53, but
nutlin-3 has shown decreased effectiveness in inhibiting MDMX-p53 interactions due
to its differential binding (199). This highlights one limitation of MDM2-targeting
agents such as nutlins: tumors with high MDMX and low MDM2 expression respond
poorly to MDM2 inhibition (170). To combat this problem, a dual inhibitor of MDM2
and MDMX (ATSP-7041) was discovered and activates the p53 pathway in vitro and
in vivo (169, 170). Another compound overcoming the limitation, NSC207895, was
found to target MDMX specifically and acted additively with nutlin-3a to activate p53
and decrease cancer cell viability (171).

1.3.3.3 SCF E3 Ligases (Excluding Skp2)
The RING-finger type SCF (Skp1/cullin/F-box) E3 ligases are the largest
family of E3 ubiquitin ligases, and they consist primarily of three core subunits: an Fbox protein that contributes to the specificity of the SCF, Skp1 (S-phase-kinase39

associated protein-1) that acts as a bridging protein and binds to the F-box, and Cul1
(One of the seven family members in the Cullin family) that forms the major
structural scaffold of the SCF. The majority of the substrates of SCF E3 ligases are
involved in regulating cell cycle progression, gene transcription, DNA replication,
and signal transduction (119, 200, 201). A growing body of evidence suggests that
phenotypes such as genomic instability, uncontrolled proliferation, and cancer result
from the dysregulation of these E3s (119), and more than a couple E3 ligases have
been proposed to be drug targets and prognostic biomarkers in cancers such as
melanoma (202). Their potential as drug targets has been only been uncovered very
recently, and as the F-box proteins provide the specificity of the SCF complex, many
small molecules have been designed to target specific members (Table 1).
SMER3 was discovered from a yeast-based screen of rapamycin enhancers,
and blocks the SCFMet30 in vivo and in vitro but not the closely related SCFCdc4.
SMER3 was also demonstrated to directly bind to Met30 and prevents degradation of
Met4, an antiproliferative transcriptional activator (203). Small molecule screens
identified SCF-I2, which inhibits the F-box protein Cdc4 in yeast but not its human
ortholog Fbxw7 (173). Its specificity can be explained by an allosteric mechanism: it
binds between two beta strands in the WD40 domain of Cdc4 that is 25Å away from
the substrate binding site. While SCF-I2 failed to inhibit Cdc4 activity in vivo, it did
show the potential of using allosteric inhibition of the WD40 domain.
Another example is BC-1215 which was recently synthesized to inhibit Fbxo3 and
blocks degradation of another F-box protein (Fbx12), which in turn degrades the TNF
40

receptor-associated factor (TRAF) adaptor proteins that are responsible for cytokine
secretion (204). This resulting TRAF inhibition by BC-1215 dampens NF-κB
activation through the TNF signaling cascade (205).
βTrCP (b- transducin repeats-containing proteins) is an E3 ligase that binds to
Skp1 and promotes degradation of a breadth of key regulatory protein elements in
cancer biogenesis, including: Pro-caspase-3, WEE1, MCL1, p100, p105 and CD4. In
most cases, it functions as an oncoprotein and has been found with upregulated
mRNA levels in many cancer types (202, 206). GS143 and Erioflorin both block
interaction between βTrCP and their targets: phospho-IκBα (nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor, alpha) and Pdcd4 (Programmed
cell death protein 4), respectively (177, 178). Inhibition of βTrCP can result in tumor
cell arrest at multiple points in the cell cycle at nanomolar concentrations and the
inhibitors show promising results in vitro (207, 208)

1.4 Skp2 in the Ubiquitination Pathway and its Role in Cancer
1.4.1 Basic Information of Skp2 and structural features
One well characterized E3 ligase is the SCF (Skp1/Cul1/F-box) complex,
which are RING-type (Really Interesting New Gene) E3s and these target a broad
range of proteins involved in the progression of the cell cycle, transcription, and
signal transduction proteins (209, 210). The Cul1 protein joins with Rbx1 to form the
RING domain, and this forms the catalytic core complex that recruits the E2 portion,
and the Skp1 acts as an adapter protein that is responsible to bind to the variable F41

box protein; this F-box protein is the variable portion of the SCF complex that binds
to the substrate, and its consensus sequence is about 50 residues long with the most
commonly repeated residue being leucine.
The most well characterized mammalian F-box protein is Skp2 (S-phase
kinase-associated protein 2; also known as FBXL1, FBL1, and p45) (Figure 6). Skp2
acts as the substrate-recruiting element of the SCF and together with Skp1, Cul1, and
Cks1 forms an E3 ligase to form the functional SCF complex. The most prominent
and arguably significant protein that is ubiquitinated by Skp2 is the CDK p27. The
protein p27 is periodically expressed in the cell cycle. Its specific phase of high
expression are at the G1 phase and it decreases at the S phase. As the levels of p27
mRNA remain stable throughout the cell cycle, it is widely considered that its protein
levels are controlled means of a posttranscriptional mechanism. Skp2/SCF primarily
targets p27 in the nucleus in the S and G2 phases. As p27 is ubiquitinated by Skp2,
there is an inverse relationship between Skp2 expression and p27 levels in multiple
tumor types as well as normal tissues (211-213).

Figure 6. Linear representation of full length sequence of human Skp2 showing
significant domains and features.
The Skp2 protein is 424 residues in length, with the F-box domain lying closer
to the N-terminal region at the 94-140 position, and the C-terminal region forming a
concave surface comprised of ten leucine-rich repeats (LRR) (Figure 7) Skp2 also
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contains a putative nuclear localization signal (NLS) within the region where Skp2
phosphorylation occurs at by Akt at Ser72, triggering Skp2 cytosolic localization
(214). The three LRRs closest to the F-box are non-canonical, while the other seven
are canonical. After the tenth LRR, the ~30 residue C-terminal tail turns back
towards the first LRR, forming what has been referred to as a ‘safety-belt’ that might
aid to pin down substrates into the concave surface formed by the LRRs (215)
(Figure 8). It is this C-terminal tail and the LRRs farthest from the F-box (repeats 610) that bind the Cks1 accessory protein, which in turn is required for the recognition
and ubiquitination of the p27Kip1 (216, 217).

43

Figure 7. General structural of Skp2 colored from N-terminus (purple) to C-terminus
(red). 2AST structure with N-terminal purple region is a homology model and
prediction of tail in unbound Skp2.
1.4.2 Functions of Skp2 Interacting proteins and Roles in Cancer
Skp2, due to its role in degrading a significant cell cycle control element, is
considered an oncogene and has been implicated in many different and diverse
cancers, including: lung carcinomas (218), neuroblastoma and gliomas (219, 220),
renal cell carcinoma (221), colon carcinoma and rectal cancer (222, 223), gallbladder
carcinoma (224), gastrointestinal stromal tumors (225), esophageal and oral squamous
cell carcinoma (226, 227), osteosarcoma (228), and cervical (229). In breast cancer, it
has been shown that Skp2 expression is associated with acquisition of epithelialmesenchymal transition (EMT) in paclitaxel-resistant breast cancer cells (230), and is
a potential biomarker for Luminal A breast cancer (231). One recent meta-analysis of
Skp2 expression that represented 5,514 patients (a large amount of which were Asian)
showed Skp2 overexpression is associated with poor overall survival as well as
disease-free survival/relapse-free survival (DFS/RFS) in all patients as well as in the
analysis of subgroups. Analysis of multiple datasets indicate that these effects are due
to amplification, and not mutation/deletion, of Skp2. Multiple studies support this
notion, showing that copy number gain is the contributing mechanism of Skp2
overexpression (232) (Figure 8).

44

Figure 8. Skp2 is commonly amplified and not mutated in many cancers. Source:
cBioPortal.com(233)
Recently some novel biological functions of Skp2 were identified and it can
activate Akt through non-proteolytic K63-linked ubiquitination for glycolysis (via
activating Glut1 expression) (234). A connection to tumor epithelial-mesenchymal
transition (EMT) has been shown to function in Skp2 also via the increased Akt1
phosphorylation and the accumulation of c-Myc during EMT by TGF-β1 signaling to
Skp2 via Akt1. Also, a recent report shows that Skp2 activates LKB1 (via K-63
ubiquitination) for cancer cell survival under energy stress via oncogenic Ras
upstream of Skp2 (235).
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It is well understood that for p27 to have its cyclin-dependent kinase inhibition
(CKI) activity in negatively regulate the cell cycle progression, it must be present in
the nucleus, and its activity is not present in the cytosol. Researchers have shown that
the inverse correlation between Skp2 and p27 is clinically associated with poorer
patient survival and increasing malignancy (213). Also significant is the fact that
multiple cancers show that p27 is frequently lost or mislocalized (and not often
mutated) to the cytoplasm, including cancers such as endometrial carcinoma
(EndoCa), renal cell carcinoma (RCC) and breast cancer (236). In fact mutations in
the p27 gene across all cancers are exceedingly rare, at a rate of only 3% (237). The
ability of p27 to block cell cycle progression is regulated predominantly by posttranslational modifications; these determine the subcellular localization and the
stability of p27. The ubiquitination of p27 is readily and quickly achieved in the
nucleus specifically by the Skp2 SCF complex when p27 phosphorylated on Thr187,
but when it is phosphorylated on Ser10, it is able to bind to CRM1 and be exported to
the cytoplasm, where there it is targeted for degradation by another E3 ligase: the
Cul1-KPC1/2 complex (238, 239).
The localization of p27 has multiple, startling effects on a cell. In the
cytoplasm, p27 can repress RhoA, which leads to: diminished focal adhesion
formation, reorganization of the actin cytoskeleton, and promotion of cell motility in
addition to promoting autophagy and inhibiting apoptosis (240). Additionally, loss of
nuclear p27 results in increased CDK2 activity and this increase results in
phosphorylation of the estrogen receptor (ER), thereby elevating ER activity and
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promoting growth of hormone-dependent tumors. These facts taken together indicate
that p27 is a tumor suppressor in the nucleus, but an oncogene in the cytoplasm.
Therefore, there are two potential targets on Skp2 that might be exploited: the
first is the Skp1/Skp2 interface. It could be disrupted, removing the rate limiting
component (Skp2) from the SCF. The other is the p27 binding site. The specificity for
p27 binding to the Skp2 SCF complex in the nucleus is made available by a pocket
formed by Skp2 and an accessory protein named cyclin-dependent kinase subunit 1
(Cks1). This pocket provides an interface on which to target specifically that could
result in the rescue of p27.
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Chapter 2: Skp2 Hot Spots and Virtual Screening for Inhibitors of Skp2
Skp2 is clearly an oncogene and acts as the rate-limiting component of the
SCF complex, and provides the specificity towards the substrate (most notably p27).
Despite its role in transferring ubiquitin to a substrate, it has no prototypical “catalytic
residue” that could be targeted like other enzymes. Skp2 also acts as an intermediate
adapter between Skp1 and the accessory protein Cks1, and the PPI interfaces formed
between both proteins is large, so conventional virtual screening techniques are likely
to fail. To circumvent this problem and to design small molecules towards Skp2, we
must target areas of the PPI interfaces in exactly the right region to disrupt the
proteins, and the consideration of hot spots have the potential to find this region.
The main thrust of this study is to combine the theory of targeting PPIs
(focusing on the theory of hot spots) and use a variety of computational techniques to
predict the hot spots that exist on Skp2. If the hot spots cluster in a specific region that
appears to be druggable (i.e., a pocket or groove), than this region will be selected as
the center region on which to conduct a virtual screen. A successful screen in which a
small molecule can disrupt the PPI and result in Skp2 unable to bind to the remaining
members of the SCF complex. This chapter describes how the hot spot analysis was
carried out, how the hot spots were selected, how the screens were conducted, and
how a small list of molecules were selected for biological testing. Finally, this chapter
shows the biological effects of the top hits.
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2.1 Materials and Methods: Development and Application
2.1.1 Selection of Compound Libraries for Virtual Screening
There were multiple iterations and multiple sources that were used for the
compound libraries. For the ligand set used in the initial Skp1/Skp2 virtual screens,
we selected the chemical library DiverSet (241) from ChemBridge. DiverSet has a
unique set of 50,080 handcrafted compounds that are derived from the Express-Pick
collection of 450,000+ compounds. The majority of these compounds have good
drug-like and lead-like molecules, with most compounds having molecular weights
below 500 and logP values less than 5, in keeping with Lipinski rules of 5 (Figure 9).

Figure 9. Distribution of molecular weight and logP of Diverset compound library
used in Skp1/Skp2 screen

For the Cks1/Skp2/p27 screening, we used a chemical library that was first
filtered so that it only contained drug-like and lead-like compounds then additional
filters using our in-house protocol to remove PAINS (pan-assay interference
compounds) to keep compounds that had logP within 1.0 to 4.0 and molecular
weights between 100 and 400 were applied. This lead-molecule like library of
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approximately 52 thousand compounds was then used as the basis for the virtual
screening using our in-house HiPCDock program.

2.1.2 Virtual Screening Methodology for Cks1/Skp2/p27 binding site
Sections of this methodology were adapted from the following publication:
“Targeting TRAF6 for Cancer Therapeutical Development”, published by the
University Of Texas Graduate School Of Biomedical Sciences at Houston in August
2012.
For the in silico high-throughput (HTS) virtual screening on the
Cks1/Skp2/p27 binding site, the 2AST structure was obtained from the PDB (242),
and the structure was prepared using the MOE software package from CCG. It is
known that Cks1 is required for Skp2-mediated ubiquitination of p27, so the Cks1
protein was included along with p27 and Skp2 (216). Previous studies of p27 and its
interactions demonstrated that mutation of Glu185 dramatically reduced the binding
of p27 to the complex while T187A mutation completely abolished the
phosphorylation of p27 (242, 243). We also found that in this structure, p27 shows
two potential regions that were pocket-like that corresponded to these two residues.
To further define the key residues to be included for virtual screening, we performed
rigorous “hot spot” predictions using routine approaches in an ensemble manner(244),
combined with molecular visualization of multiple SCF complex structures(206, 242,
243, 245).
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Instead of performing one screen that covered both pockets, we performed
three screens; two separate and exhaustive jobs were carried out on only the two
individual pockets, and a final larger screen that covered both pockets together. The
resulting hits from these screens were biased towards those that were present in both
pockets. However, the majority of the top selected hits were found to occupy the
Glu185 pocket. The top performing results from GOLD were visualized and
examined for their ability to cohabitate both of these regions.
The resulting top 5,000 hits (based on docking scores and docking poses) were
then docked using GOLD by CCDC. The top scoring 500 ligands (by GoldScore)
were visualized individually (using PyMOL) in their docked conformation with the
original submitted Skp2 2AST structure. Three main criterions were considered in the
final selection of 500 hits. The first criterion was the degree to which the ligands’
conformation occupied the interaction site between p27 and Skp2/Cks1. Second, the
conformation, binding affinity, and resulting “fit” within the p27 binding site
compared to the corresponding Skp2 residues was considered. Each ligand, given its
orientation in the docked position, was evaluated on its ability to potentially block the
binding of p27 protein by considering hydrogen bonds, electrostatic and aromatic
interactions. The third and final consideration was the distinctiveness in the
chemotypes when compared to other ligands. We placed the ligands into “classes”
based upon the individuality of their underlying scaffold and how this scaffold was
oriented in the binding site. Ligands that shared a similar scaffold and orientation
were considered to be in the same class, and would then share the same chemotypes.
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Also for the selected 500 hits, we assigned a “priority” to each molecule which was an
aggregate of the second and third factors (conformation in the pocket and
distinctiveness). This priority was defined as: low, medium or high. The priority then
became similar to a degree of confidence for each ligand. Compounds with “high”
priority were regarded as most likely to yield good biological activity, and should be
tested over the other low and medium confidence ligands. Eventually from the 500
hits, we selected 123 unique compounds with high priority that were recommended to
be tested for biological activity. In addition to these 123 unique compounds, based on
the core scaffold of compound 405, a search of structurally similar compounds (also
called a SAR by catalog) was carried out and identified 41 compounds that were
analogues of compound 405.

2.1.3 Virtual Screening Methodology for Skp1/Skp2 binding site
The high-quality and most comprehensive crystal structure of Skp2 was
obtained from the Protein Data Bank(246) (2AST) and the B chain (Skp2) was
analyzed in complex with the A chain (Skp1)(242). The N-terminal tail has not been
crystalized on this structure, but the rest of the protein (the F-box, the LRR domain,
and the seatbelt region) is present in this structure. In fact, the N-terminus has never
been crystallized on Skp2. Water molecules along with the C and D chains were
removed from this 2AST crystal structure via PyMOL (247). From the literature, the
19 residues on Skp2 in contact with Skp1 formed the basis for detecting druggable
sites in the F-box region of Skp2 (243). The first region (pocket 1) was close to the N52

terminus of Skp2, and the second region (pocket 2) had close proximity to the
corresponding C-terminus of Skp1. The software MOE(248) and its site finder
function validated the second pocket region on Skp2 within the F-box for which to
dock small molecules to. Since the two regions (referred to as pocket 1 and pocket 2
henceforth) appear to have distinct differences in their surface area, size and location
on Skp2, the two pockets were treated as separate virtual screens, each with a unique
center and size.
The broad methodology for the virtual HTS on this region of Skp2 was similar
to that for the Skp2/Cks1/p27 binding site. The docking program used, HiPCDock
(249), is based upon DOVIS (250). The program considers a 3-dimensional cubic
region with user defined coordinates, and the centers of these cubes were placed in the
binding sites for each docking study. Pocket1 was centered at AutoDock coordinates
1.134, -114.378, -1.751 (x,y,z) and grid points of 80 in each dimension. Pocket2 had a
center of -1.962, -100.846, 10.708, grid points of 48 in each dimension. Both virtual
screens had genetic algorithm parameters of 100 runs, a population size of 100, and
rate of crossover at 0.8. Further details (configuration files) of HiPCDock and the
docking parameters used are available in the appendix.
After the initial docking of DiverSet, the 2000 compounds with the best
HiPCDock scores for each pocket were then docked again into the same receptor
(Skp2) using the GOLD (Genetic Optimization for Ligand Docking) software
suite(251) to further narrow down the top binders using a scoring method different
from HiPCDock. GoldScore was chosen as the fitness function, and a radius of 10Å
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was used. The centroids were defined in the same manner as the HiPCDock, and a
cavity file was generated from the selection. Further specific parameters used in the
GOLD docking are available upon request.
The resulting top scoring 200 ligands from each pocket on Skp2 with the
highest GOLD fitness values were then structurally clustered based on structural
MACCS (Molecular ACCess System) fingerprints using MOE fingerprint clustering.
The metric used was the Tanimoto coefficient, and the similarity and overlap were set
to 60%. After clustering based on these fingerprints, the cluster center ligands from a
given cluster are retained. The resulting 120 ligands from this clustering (70 ligands
for pocket1, 50 ligands for pocket2) were then individually visualized (using PyMOL)
in their docked conformation. Three main criterions were considered in the final
selection process. The first criterion was the degree to which the ligands’
conformation occupied the interaction site between Skp1 and Skp2. If the
conformation primarily existed outside of the interaction site, it was no longer
considered a candidate. Second, the conformation, binding affinity, and resulting “fit”
within the Skp2 binding site compared to the corresponding Skp1 residues was
considered. Each ligand, given its orientation in the docked position, was evaluated on
its ability to potentially block the binding of the Skp1 residues. Along with these
potential blocking effects, we also considered the binding affinity of the ligand in its
pocket. This included qualities such as hydrogen bonds, static and aromatic effects.
The third and final consideration was the distinctiveness in the molecular scaffold
when compared to other ligands for each pocket. We placed the ligands into “classes”
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based upon the individuality of their underlying scaffold and how this scaffold was
oriented in the binding site. Ligands that shared a similar scaffold and orientation
were considered to be in the same class, and would then share the same class number.
We then assigned a “priority” to each molecule which was an aggregate of the second
and third factors (conformation in the pocket and distinctiveness). This priority was
listed as: low, medium or high. The priority then became similar to a degree of
confidence for each ligand. Compounds with “high” priority were regarded as most
likely to yield good biological activity, and should be tested over the other low and
medium confidence ligands. The result from this visual selection process was that 57
ligands in total were recommended to be tested for biological activity; 41 total ligands
were chosen as compounds to be tested for pocket1 with 16 compounds listed as high
priority. For pocket2, 16 total compounds were selected, and 11 of these were high
priority. Only the high priority compounds were actually tested biologically, and two
of the ligands (7957666 and 9040817) were included in both of the pocket 1/pocket 2
lists; this lead to a final total of 25 compounds ordered for biological testing.

2.1.4 Biological testing by Collaborators
Cell culture and reagents
293T, PC3, A549, H460, H1299, Hep3B and U2OS cells were cultured in
DMEM containing 10% FBS while LNCaP and H3255 were cultured in RPMI-1640
medium containing 10% FBS. (His)6-ubiquitin, GST-Akt, and HA-Akt constructs
was described previously. (252) Flag-Skp2 was a gift from Dr. W. Wei. GST-Skp2
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Trp97Ala (W97A) and GST-Skp2 Asp98Ala (D98A) mutants were generated in
pGEXSkp2ΔN-Skp1Δ, a gift from Dr. B.A. Schulman, by site-directed mutagenesis
assay according to manufacturers’ standard procedures (Stratagene). ZL-25 and its
analytical data including 1H, 13C NMR and LC-MS/MS analysis were obtained from
ChemBridge. LY294002 was purchased from Cell signaling.

LC-MS/MS analysis of the in vitro binding between Skp2 and Skp2 inhibitor.
GST-Skp2 W97A and GST-Skp2 D98A mutants used for demonstrating #25Skp2 interaction were generated in pGEXSkp2ΔN-Skp1Δ bicistronic co-expression
constructs. Subsequently, the GST-Skp2 WT, GST-Skp2 W97A and GST-Skp2
D98A mutants were co-expressed, purified and formed complex with Skp1 (Δ38–44
aa.) as described previously (253). The purified proteins were incubated with ZL-25
for overnight at 4°C, and the GST tags were thrombin-cleaved and pulled-down by
glutathione sepharose beads (Invitrogen). The untagged protein samples were pHadjusted by adding 50mM ammonium bicarbonate and digested by adding 200 ng
modified trypsin (sequencing grade, Promega) for 18hrs at 37°C. The resulting
peptides and compound were analyzed by LC-MS/MS on an Orbitrap-Elite mass
spectrometer (Thermo Scientific, Waltham MA). Proteins were identified by database
searching of the fragment spectra against the SwissProt (EBI) protein database using
Mascot (v 2.3, Matrix Science, London, UK). Typical search settings were: mass
tolerances, 10 ppm precursor, 0.8d fragments; variable modifications, methionine
sulfoxide, pyro-glutamate formation; up to 2 missed cleavages. The extracted ion
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chromatograms (XICs) for the bound compounds were examined and peak heights
were analyzed and quantified by using Qual Browser (Thermo).

2.2 Results: Predicted Hot Spot Residues for Virtual Screening
2.2.1 Hot Spots on Skp1/Skp2 interface
The Skp1-Skp2 interface is interdigitated, with alternate structural elements from
protein interlocking with the other. The middle F-box domain of Skp2 and Skp1 Cterminal helix (H8 helix) are sandwiched between the other Skp1 helices on one side
and the first LRR and C-terminal safety-belt on the other side. This interface has been
described as having a variable and a core interface from the F-box perspective. In the
core interface, the F-box packs with the H5, H6, and H7 helices of Skp1. It is referred
to as the core interface because it accounts for two-thirds of the surface area buried,
(2,050 Å2) and contains residues conserved in all Skp1 and F-box protein
members(243). The variable interface was defined as the opposite face of the F-box
packing with the H8 helix of Skp1 and also with the first LRR and C-terminal end of
the safety-belt (an area of 930Å2). The structural elements in the variable interface are
conserved in Skp1 and Skp2 orthologues, but not in other F-box and Skp1 family
members, particularly in the H8 helix (243). This is not to say that the variable region
does not contribute to binding. An in vitro assay that compared dissociation of the
Skp1-Skp2 complex with that of a F-box-Skp1ΔH8 complex, which has a core
interface structure similar to the original but lacks all of the elements unique to the
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variable interface, showed half-lives of greater than 9 hours and less than 30 minutes,
respectively(243).
The SiteFinder program in MOE (Chemical computing group) was used on the
2AST crystal structure, this program does not consider hot spots but uses simple
proximity-based rules of connectivity. Also, the HotPoint, FTMap, as well as KFC2A
and KFC2B models were used on the same structures. For each of these jobs, the
2AST structure was stripped of all other proteins/solvent molecules/waters, leaving
only the Skp2 protein. Default parameters were used for the HotPoint models, and
KFC2 was submitted the refined PDB structure, as the entry of the PDB code on the
web server gave an error. KFC predictions were showing highly inconsistent results
with the HotPoint and MOE site finder predictions, including suggestions on both
Skp1 and Skp2 where residues had their side chains slightly buried and predictions of
residues with smaller sidechains where it was not obvious as to how these residues
interactions between Skp1 and Skp2 were possible. The KFC results were not
discarded, just given less weight in the final ensemble consideration. Also, FTMap’s
prediction was biased towards pockets of the Cks1 binding site, but did find regions
that were closer to Skp1. The top ranked cluster centers (the areas with the most
docked pharmacophores) were corresponding to the Cks1 binding site (Figure 10).
The top ranked cluster centers that were not in the Cks1 binding site region (in the
LRR domain) actually corresponded to areas where HotPoint and SiteFinder both
predicted there were concentrations of hot spot residues. These regions were close to
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the Skp1-facing H1 helix on Skp2, and the region just behind the H2 and H3 helixes
of Skp2, facing the beginning of the LRR domain.
To bolster the predictions, structural analysis was carried out on the contacts
between Skp1 and Skp2 based on distance and hydrophobic interactions. Overall,
HotPoint faired the best in predicting the contacting residues, but was biased towards
residues that were larger and bulkier.

Figure 10. FTMap results of Skp1/Skp2 (blue/green) hot spot predictions. Top
scoring cluster centers were in the Cks1 binding site, but centers 3, 5, as well as 6/7
showed good consensus to other hot spot predictions and residues contacting Skp2.

Based on visualization analysis as well as literature reports(242) there are 19
residues on Skp2 in contact with Skp1 and they form the basis for detecting druggable
sites in the F-box region of Skp2 (206, 242, 243). The consensus of the hot spot
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prediction tools as well as the SiteFinder results suggested we group Skp1/Skp2
contact sites into two pocket-like and distinct regions (Table 3).
Residue
Name Chain RelCompASA RelMonomerASA Potential Prediction
Number

95
V
B
62.3
115.13
12.39
96
S
B
58.17
73.11
2.13
97
W
B
3.16
61.76
32.59
Hotspot
99
S
B
69.61
80.8
8.13
100
L
B
0.13
23.79
41.47
Hotspot
101
P
B
30.39
44.78
7.19
104
L
B
2.83
49.91
31.55
Hotspot
107
G
B
30.84
48.2
10.65
108
I
B
0.87
47.88
39.69
Hotspot
111
C
B
30.5
82.75
20.49
112
L
B
2.32
24.76
32.47
Hotspot
114
L
B
0.08
5.13
61.89
Hotspot
116
E
B
16.96
37.81
8.76
118
L
B
11.62
54.47
37.19
Hotspot
119
K
B
25.6
66.17
4.7
121
S
B
6.27
19.42
13.14
122
G
B
25.04
87.07
5.36
123
V
B
2.78
60.03
17.75
124
C
B
12.56
43.95
12.65
125
K
B
53.92
91.3
8
127
W
B
4.73
26.39
33.1
Hotspot
128
Y
B
35.12
65.45
18.64
142
L
B
0.58
4.03
47.82
Hotspot
145
K
B
18.99
39.77
8.64
154
R
B
27.56
52.86
19.44
155
L
B
0.85
9.75
54.63
Hotspot
Table 3. Consensus of HotPoint prediction of hot spot residues on Skp2 based on
2AST structure. Two pockets were selected based on the two groups of the hotspots.

Trp97, Leu100, Ile108, and Val120 were predicted by all three methods to be hot
spots, and Trp127 was predicted to be a hot spot by KFC2B and HotPoint. The first
region (referred to henceforth as pocket 1) is close to the N-terminus of Skp2 and is
actually within the F-box motif, including Trp97, Phe109, Glu116, Lys119, and
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Trp127. The second region (referred to henceforth as pocket 2) has proximity to the
corresponding C-terminus of Skp1, formed by the first and second LRR as well as
some residues from the F-box, essentially around the variable interface of the F-box
region of Skp2 (Figure 11).

Figure 11. Identified binding pockets on the Skp12/Skp2 complex. Skp2 (molecular
surface: gray for carbon, blue for nitrogen, and red for oxygen atoms). Skp1 (purple
ribbon). Cyan (Skp1 residues interacting with Skp2).
2.2.2 Hot Spots on Cks1/Skp2/p27 interface
After the consensus analysis of the KFCA, KFCB, PCRPi, and HotPoint
programs, the residues determined to be the most significant for binding were found
to center around the PhosphoThreonine187 (TPO187) and Glu185 residues of the p27
peptide (Figure 12). We selected the residues for which to do virtual screening (using
the GOLD software) based on these two regions (calling the region around Glu185
“Pocket1” and the region around T187 “Pocket2”) and, applying techniques similar to
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those in de novo drug design, we biased our results towards hits that showed similar
properties and positions to that of the residues in those areas.

Figure 12. Cks1/Skp2/p27 binding site. TPO187 and Glu185 are both significant for
binding. Virtual screens were centered on these two points separately, and one screen
included both points together.
The residues that were selected on Cks1 were: Tyr8, Ser9, Lys11, Arg20,
Glu40, Arg44, Gln49, Gln50, Ser51, Gln52, Trp54, and Arg71. For Skp2, the residues
were: Arg294, Asp319, Arg344, and Tyr346 (Table 4. Consensus of 4 hot spot
predictions on the Skp2/Cks1/p27 interaction site. Residues selected as hot spots
highlighted in orange or red.) (Figure 13).
Essentially, this was a more straight forward hot spot prediction, as the p27
surface area residues that are contacting Skp2 and Cks1 are much smaller and less
intricate than the Skp1/Skp2 interaction site. Most of these residues closely resembled
the ones that are in contact with p27 peptide, and, as was mentioned previously, it is
known that mutations on the Thr187 and Glu185 residues abolish or significantly
impact the ubiquitination of p27(242). Residues with at least two programs reaching a
consensus were considered “mild” hot spots (highlighted in orange), while more than
62

two consensus predictions were considered “strong” hot spots (highlighted in red).
The number of polar contacts were also calculated by MOE and PyMOL, and these
also had good agreement with the PCRPi and KFC2 models. HotPoint was perhaps
overly sensitive in this prediction space with many potential false positives, but it had
no false negatives.

Figure 13. Hot spot residues for Cks1 (blue)/Skp2 (green) interface.

Chain Res# Res Hotpoint KFC2A KFC2B
B
B
B
B
B
B
B
B
B
B

265
291
294
318
319
343
344
368
393
398

Trp
Ser
Arg
Ser
Asp
Ser
Arg
Phe
Trp
Arg

C
C

35
36

Thr
His

H
H
H
H
H
H
H
H

H

H

H

H

H

H
H

H
H

1
13
2
4
9

H
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PCRPi Polar
Rank Cntacts
3
1
1
8
1
9
7
1
4

3

C
37 Leu
H
H
H
10
2
C
38 Met
H
C
40 Glu
H
2
C
41
Ser
H
H
1
3
C
42 Glu
H
H
H
3
3
C
44 Arg
H
5
C
45 Asn
H
H
6
Table 4. Consensus of 4 hot spot predictions on the Skp2/Cks1/p27 interaction site.
Residues selected as hot spots highlighted in orange or red.
In conclusion, HotPoint and KFC models appeared to have the best predictive
capacity for the two interaction sites on Skp2, but the use of a larger consensus
(programs such as FTMap and PCRPi), as well as a visual and robust structural
analysis was needed to increase the confidence in the predictions. HotPoint appear to
perform better for larger and more elaborate surface area interactions (the Skp1/Skp2
interaction), and its potential bias towards larger residues is a means by which it can
have this strength, but it hinders for smaller interactions. Other studies have shown it
to be highly sensitive when compared to other methods (254). FTMap and KFC (and
to a lesser extent, PCRPi) showed their strength in the smaller sites, but performed
poorly on the larger complexes. The performance of KFC on smaller sites is likely
due to their use of a training set that primarily involves hormones, inhibitors and
small fragment proteins, and not many large complexes (84).
These predictions formed the basis for the sites (the general area as well as
which specific residues to focus on) on which to perform the virtual screening. The
centroid of the screen was selected such that the area encapsulated by the docking
program (GOLD uses a radius, HiPCDock uses a cubic unit) contained all the residues
selected as hot spots.
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2.3 Results: Evaluation of Skp2 Virtual Screening
2.3.1 Ligands Submitted for Testing for Skp1/Skp2 interface
For the Skp1/Skp2 virtual screen, 41 total ligands were chosen as compounds
to be tested for pocket 1 with 16 compounds listed as high priority. For pocket 2, 16
total compounds were selected, and 11 of these were high priority. Again, we
assigned high priority to the compounds in which we had the highest confidence in
these being active biologically based on their pose and diversity in the virtual screen.
Only the high priority compounds were ordered for testing in the thought that if none
of the high priority compounds were active, the medium and low priority compounds
would be selected for a second round of testing.
HiPCDock Results: The HiPCDock docking scores of the 50,080 compound
DiverSet library into pocket 1 and pocket 2 are summarized below (Table 5). The
histograms of the energies are close to extreme value distribution, and are displayed
below (Figure 14), (Figure 15).
Pocket 1 Pocket 2
Mean

-5.43

-4.12

Median

-5.39

-4.14

Mode

-5.55

-4.23

Maximum

-0.83

-0.00026

Minimum

-12.31

-10.95

Standard Deviation

1.138

1.18

Table 5. HiPCDock docking sores of DiverSet into Pocket 1 and Pocket 2
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Figure 14. Histogram of energies of Pocket 1 HiPCDock docking results.

Figure 15. Histogram of energies of Pocket 2 HiPCDock docking results.

Gold Results
In GOLD, the default scoring function is the GoldScore; this is comprised of
four components from the equation:

f = S hb _ ext + S vdw _ ext + S hb _ int + S vdw _ int
Where Shb_ext is the protein-ligand hydrogen bonding score and Shb_int is the internal
hydrogen bonding of the ligand. Svdw_ext and Svdw_int are the scores arising from weak
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external and internal Van der Waals forces, respectively. The top Gold fitness scores
for the 4,000 compounds (2000 for pocket 1, 2,000 for pocket 2) are summarized
below in table form (Table 6), and histograms (Figure 16), (Figure 17).

Pocket 1 Pocket 2
Mean

37.76

35.65

Median

37.93

35.91

Mode

42.01

36.84

Maximum

62.55

56.15

Minimum

-44.99

8.29

Standard Deviation

8.59

5.54

Table 6. Gold docking sores of DiverSet into Pocket 1 and Pocket 2

Figure 16. Histogram of energies of Pocket 1 Gold docking.
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Figure 17. Histogram of energies of Pocket 2 Gold docking.

The biological testing of the Pocket 2 compounds revealed almost all
compounds were poor binders except for one: 9040817. However, investigation of the
mechanism revealed it was not acting in the mechanism we proposed. Also, secondary
screens were showing that 9040817 was not effective (Table 7. Top 16 Compounds
selected for biological testing for Pocket 2. Ligands marked as “High” priority were
tested biologically. Most of these compounds were not active except for 9040817.
).
Auto
Gold
#

Structure

ID

In vitro
Dock

Class Priority

Fitness

binding
Score

O

>100

S
O
N

1

N

HN
N

N
H

7974443

56.15

-6.47

1

High
µM

68

O

N

2

>100

N

7694040

S
N

N
H

N
H

52.21

-8.35

2

High
µM

Cl

>100

N
S

3

9043923

N

N

N

-7.05

3

High

N

µM
Cl

Cl
H
N

H
N

4

51.75

Not
7839261

S

N

N

Cl

50.81

-6.31

4

Med
tested

Cl

Cl

Not

N
N

5

N

N

9043648

NH
O

N

6

50.12

-6.89

3

Med

Cl

tested
>100

OH

N

9037036

N

47.94

-6.5

5

High
µM

N

Not

O

7

5570289

S
N

47.31

-6.2

6

Med

O

tested

N

>100

S
N

8

N

7818158

HN

47.28

-6.4

7

High
µM

F

9

Redacted

Redacted

47.27

-6.68

8

High

O

10

>100
7740910

N
H

N

46.89

-6.7

9

High

N

µM

Not

Cl
N

11

O
N

Cl
N

F

5 µM

7739449

46.79

-6.91

3

Med
tested

N

69

OH

N

O

>100

N

N
N

12

9062916

46.43

-6.42

10

High
µM

O

O

N

13

N

7957666

46.39

-6.51

11

High

7726220

46.27

-8.56

3

Low

100 µM

N

HN
O

H
N

Cl

Not

N
N

14

O

N

N

N

tested

NH2

Br

NH

15

O

7631104

N

46.11

-8.01

12

High

100 µM
>100

O
N

N

16

S

Cl

6037495

O

45.64

-6.18

7

High

µM

N
H

Table 7. Top 16 Compounds selected for biological testing for Pocket 2. Ligands
marked as “High” priority were tested biologically. Most of these compounds were
not active except for 9040817.

Auto

Cell

Gold
Structure

In Vitro

ID

Dock Class Priority
Fitness

Sensitivity
Binding
(IC50)

Score
N

N

8

9040817

NH
N

N

57.31

-8.19

3

High

5 µM

>20 µM

S
O

19

Redacted

Redacted 54.47

-8.04

10

High

5 µM

5 µM

35

Redacted

Redacted 51.46

-8.52

14

High

5 µM

5-10 µM

39

Redacted

Redacted 51.17

-8.03

17

High

5 µM 10-20 µM

-7.95

18

High

5 µM

5572358

O

41

HO

N

50.71

N

O

S

(ZL-25)

70

5-10 µM

Table 8. Results of cell sensitivity (secondary screen) studies. Ligands #35 (which
has its structure redacted) and #41 (5572358) were found to be the most sensitive and
fit the mechanism of action.
The top performing compounds from both pocket 1 and pocket 2 were
submitted to cell sensitivity studies. The Cell sensitivity studies showed that
compounds Redacted and 5851912 did not fit the mechanism proposed. These likely
were achieving the sensitivity values due to another, off-target mechanism of action
(not via targeting Skp2 and p27 ubiquitination) and were not pursued further. The
compounds that were found to be most active and fit the mechanism were 5572358
(which became the lead, ZL-25), and a second compound (which was also known
internally as ZL-22). ZL-22 was only slightly less active than ZL-25, so ZL-25
became our primary lead.

2.3.2 Ligands Submitted for Testing for Cks1/Skp2/p27 interface
In regards to the Cks1/Skp2/p27 site, the unique features of this particular
target required a more unconventional approach in regard to the virtual screening
methods. The crystal structure shows that Cks1 binds to the concave leucine-rich
repeat (LRR) domain on Skp2 (the interface buries ~ 1850Å2 of solvent accessible
surface), and p27 forms contacts with both Cks1 and Skp2, with interface sizes of
~740Å2 and ~400Å2, respectively. These interfaces form what is essentially an
atypical, three-part protein complex on which we focused our inhibitor design efforts.
The use of three screens covering the two pockets individually and then both taken
simultaneously was used to maximize the possibility of discovering a ligand large
enough that could hit both pockets together, (such that might have a stronger potential
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to block p27 binding) but still retaining the potential of finding a ligand that had a
high affinity for only one pocket. The top hits from the two smaller targeted screens
were merged into only 5 compounds with high priority that were tested (Table 9).

Gold
#

Structure

ID

MolWt

logP

Score
N

HN

1

O

ST02940

O

O
S

3.03
65.9258

438.50

5

O

3

O

2

ST04175

S

N

O

H
N

N

S

2.72
65.8194

376.43

6

9

O
-

O

O

OH

O

-

2.33

N

O

R732486

3
N

HO

N

H
N

N

62.0391

283.30
3

OH

N

0.53

O

4

S

N

S
O

N

312.35
4

H
N
N

61.2877

O

N

N

5

R549606

-

S

ST02735

F
F

3.45
60.3729

O

5

O
F

395.36
1

Table 9. Top hits from two small targeted screens with high priority that were
biologically tested. #1 (ST029405, referred to later as ZM-405) was found to be active
and fit the mechanism.
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From the wide screen that incorporated both pockets, there were 14
compounds selected, five were considered high priority. Due to the low number of
compounds listed here, all were ordered and all were tested (Table 10).

Gold
#

Structure

ID

MolWt

logP

75.95

454.80

3.372

74.82

415.38

3.506

73.99

395.77

2.737

73.44

463.42

3.543

73.057

482.51

1.92

72.54

427.41

3.176

Score
O
-

+

N

O

O

ST01693

HN

1

O

N

O

O

9

OH
-

Cl

O

O

ST03131

-

O
N
H

2

O

N

O

2
O

O

ST02463

O

O
N
H

Cl

3
O

4

N
-

O

-

O

O

O

4

ST03137

S

O
N

-

O

O

O

8

O

H
N

O
S

S

N
O

5

ST04003

O

O
N

3

-

O

O

ST01190

H
N
O

6

O
O

-

O

O

8

N

S

O

N
H

N

73

O
O
NH
O
S

S
O

7

R508276

72.09

407.48

2.381

72.06

533.39

3.759

71.68

375.40

2.125

71.29

451.43

3.476

71.26

354.40

2.375

71.24

431.48

2.708

71.19

428.81

3.674

HN
O

Br
O

8

ST00433

H
N

O

O

S
N
O

O

8

O

O
H2N
S
O

O
O

+

N

9

-

ST03189

O

N
H

7

NH

O
HN

O

ST01692

O

10

O

1
O
+

N

O

-

O

O
O

11

O

ST02409

S

-

O

N
H

O
-

O

O

1
H
N

S

ST04018

O
O

12

O
N
H

6
O
+

N

Cl

O

N

ST02117

O

13

N
H

N

NH

-

O

3
O

74

O
H
N

H
N
N
H

14

O

-

O

O

L440442

O

70.76

398.39

1.78

O

Table 10. Selected compounds for testing from broad based screen covering both
T187 and Glu185 pockets. #14 (L440442, later known as ZM-442) was originally
considered active in initial screens but was not confirmed in secondary assays.

2.3.4 Discussion of findings from Virtual Screens
The 2AST crystal structure was chosen for its high resolution and its inclusion
of the p27 and Cks1 peptides. Consideration of the residues that contacted Skp2 from
Skp1 was a crucial step in understanding which sites would lead to the disruption of
this complex, and the site finder in MOE helped to validate pocket 2 as a reasonable
location to perform one of the virtual screens. The choice of the DiverSet library as
the primary screening ligand set ensured that adequate chemical diversity was present
in the virtual screening. The diversity stems partially from the more than 260,000
unique 3-point pharmacophores present within DiverSet. It has high diversity in druglike compounds, and applied filters remove unsuitable compounds such as:
undesirable chemical groups (e.g. Michael acceptors, crown-ethers & analogs,
disulfides, epoxides), structural, salt and tautomeric duplicates (241).
Using HiPCDock as the first High-Throughput Docking (HTD) tool for
screening because of its, speed, efficiency and ease of use in a High-Performance
Computing, multiple-CPU cluster environment. Its basis on the AutoDock framework
allows for easy automation and high levels of control over the parameters involved,
and its statistical-based bioinformatics model towards structure-based HTD gives it an
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advantage over other docking tools. The binding free energy distribution is very close
to extreme value distribution, which allows us to calculate the probability and
expectation of the binding free energy of the ligand-receptor complex; from these
calculations, a statistical significance of the prediction can be evaluated.
By docking the top results from HiPCDock into GOLD, we were able to
utilize a consensus method to enhance the probability of finding active compounds.
GOLD has been shown in multiple studies to have high accuracy in the prediction of
binding modes of ligands and it is a more than acceptable program for its use in
various techniques when compared with other docking or virtual screening programs
(255-257). The clustering of the GOLD results based on MACCS fingerprints
increases the relative diversity of the pool of molecules selected for biological testing
and removes structurally similar compounds.
The top scoring 130 compounds cluster centers were visualized individually
by hand in PyMOL to maximize the potential of finding ligands that would prove to
be active biologically. This higher scrutiny at this stage not only ensured that there
was more than adequate diversity in the final compounds; it confirmed that the
compounds resided in the desired interaction site and therefore had a high potential of
inhibiting the interaction with Skp1. Also of note, our analysis was independent of the
two docking scores that we obtained; this made for our analysis to be more qualitative
than quantitative.
Skp2, when in complex with the different bound forms of each ligand, gives
us insight as to what features lead to this good activity. The ligand 5572358 (the 41st
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entry in the above table, referred to as ZL-25 in the remainder of this study), when
docked to Skp2, is indicative of the structures of other ligands that showed high
docking scores, and good biological activity. Also of note is the pi stacking occurring
towards Trp97, with an average distance of 3.27Å to this residue. The ligand ZL-22,
which also shows good biological activity, also shows a single hydrogen bond, but
occupies a lipophilic region bound by Ile108, Trp127, Phe109, and Leu105. Again,
the pi stacking appears to be strong between the ZL-22 ligand and the Trp97 residue,
with an average distance of 3.1Å.

2.3.4 Summary of findings from Virtual Screens
In total, from the initial virtual screens there were two compounds initially
considered leads for both Skp2 regions. ZL-25 and ZL-22 for the Skp1/Skp2 interface
(Figure 19), and ZM-405 with ZM-442 for the Cks1/Skp2/p27 project (Figure 18).
From these, ZL-25 and ZM-405 were considered the primary leads on which lead
optimization would be performed (Figure 20).

Figure 18. Top two p27 inhibitors discovered via virtual screen (left) and proposed
binding poses (right). Compound ZM-442 (blue sticks) covers both pockets (Thr187
and Glu185), whereas compound ZM-405 (purple sticks) is predicted to bind to just
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the Glu185 pocket. Both compounds are capable to block p27 binding (shown in
yellow sticks).

Figure 19. ZL-25 in proposed docked position on Skp2. Significant residues for
binding circled.

Figure 20. Structures of the two Skp2 inhibitor leads: ZL-25 (left), ZM-405 (right).

2.4 Results: Biological Effects of Virtual Screening Results
2.4.1 In Vitro and In Vivo Data of Skp1/Skp2 inhibitor ZL-25
Portions of this data used with permission from the journal Cell, in the article:
“Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem
Cell Traits and Cancer Progression” Cell. 2013 Aug 1;154(3):556-68. (176)
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Our collaborators performed the biological testing of the suggested
compounds, the effects of the compounds are presented here. The initial in vitro
binding assay/screen that identified ZL-22 and ZL-25 was a simple GST-Skp1 pulldown assay at 5µM showing that it was able to completely prevent Skp1-Skp2
interactions (Figure 21A.) and do so in a dose dependent manner in PC3 cells
(Figure 21B). Next, our collaborators tested the ability of ZL-25 to reduce the levels
of ubiquitinated p27 in vitro with a Skp2-mediated ubiquitination assay, and again it
was able to achieve these effects in the sub-10µM range resulting in their stabilization
(Figure 22).

Figure 21. A. In vitro binding assay of Skp1-Skp2 with our without ZL-25 (far right
lane). B. In vivo dose dependent Skp1-Skp2 binding assay in PC3 cells.
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Figure 22. ZL-25 is able to inhibit Skp2-mediated p27 ubiquitination in vitro.

Additionally, consistent with the ubiquitination assay of p27, a dosedependent induction in the fold change of p21 (another substrate of Skp2) and p27
was seen in PC3 (prostate cancer) cells is apparent with ZL-25. It is not readily
apparent as to why the 1µM dose seems to result in a small decrease in the fold
change of p21 and p27 (Figure 23).
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Figure 23. Induction of p21 and p27 via ZL-25. PC3 cells were treated with DMSO
or ZL-25 at different doses for 24hrs and harvested for immunoblotting (IB) assay.
As Akt is a substrate of Skp2 for K63-linked ubiquitination and Skp2 is
responsible for its activation via this mechanism, ZL-25 was also shown to inhibit
Skp2-mediated ubiquitination both in vivo (293T cells) and in vitro (Figure 24).

Figure 24. ZL-25 also affects other Skp2 substrates, such as Akt. A. In vivo Akt
ubiquitination assay showing dose dependent inhibition. B. In vitro Skp2-mediated
Akt ubiquitination assay.
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2.4.2 Confirmation of Binding Mechanism of ZL-25
The predicted binding mode of ZL-25 shows several primary interactions with the
F-box domain on Skp2. Most notable are the Trp97, Asp98, Arg126, and Trp127
residues (Figure 25). Other nearby residues that contribute to Skp1 binding but not
ZL-25 binding include Pro101, Leu105, Ile108, and Phe109.

Figure 25. Proposed docking mode of ZL-25 to Skp2 F-box domain. Highlighted
residues contribute significantly for ZL-25 binding.
To determine the residues responsible for binding to both Skp1 and to ZL-25, sitedirected mutagenesis was carried out on all the above residues. The mutant proteins
had their residues mutated to alanine (since it is the least reactive amino acid that does
not introduce torsional freedom). Of the mutants Skp2 proteins, only the Skp2
Trp97Ala, Asp98Ala, and Trp127Ala retained their Skp1 binding ability, the others
lost their Skp1 binding capacity, but it is worth noting that Ile108 retained 50% of its
binding affinity to Skp1 (Figure 26). Among the proteins that retained all their Skp1
binding ability the biological activity of Trp97A, Asp98A, and Trp127A were tested
for their capacity to bind to ZL-25. It was demonstrated that Trp97A and Asp98A are
82

resistant to the effects of the inhibitor, which confirms that these residues are
responsible for binding ZL-25 to Skp2 and that the predicted binding mode of ZL-25
from the virtual screen is accurate (Figure 27).

Figure 26. 293T cell Skp1-Skp2 binding assay. W97A, D98A, and W127A all
retained their ability to bind to Skp1.

Figure 27. 293T cell ubiquitin binding assay transfected with different mutant
constructs and in the presence or absence of ZL-25.
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In addition to this mutant data, cell survival was examined of WT Skp2 versus
the W97A and D98A mutants. The effect of ZL-25 was examined on survival in two
types of prostate cancer cells: Skp2-knockdown and control mutants dosed with ZL25. The inhibitor had capable effect on the viability of control-knockdown cells in a
manner that was dose-dependent, its effects were compromised when compared to the
Skp2-silenced cells (Figure 28).

Figure 28. PC3 cells with or without Skp2 knockdown (A) or PC3 cells stably
expressed with Skp2 WT, W97A, or D98A mutants (B) treated with various doses of
ZL-25, followed by cell survival assay. Cell survival percentage of each stable cell
lines treated with various doses of ZL-25 was normalized to that treated with DMSO.
Results are presented as mean values ± SD. ∗p < 0.05; ∗∗p < 0.01.
Next, to determine the specificity of ZL-25, two other highly similar F-box
proteins (specifically Fbw7 and β-TrCP) were selected for their potential binding to
ZL-25. Despite the drastic effects of ZL-25 on Skp2-mediated ubiquitination of p27
and Akt by Skp2 (shown above), the inhibitor showed no appreciable effects on βTrCP-mediated ubiquitination of Snail and IκBα (two of the targets of β-TrCP) (258),
as well as Fbw7-mediated ubiquitination of c-Jun and MCL-1 (two well described
targets of Fbx7) (reviewed in (259)) (Figure 29).
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Figure 29. ZL-25 is specific towards diminishing E3 activity of Skp2, but not other Fbox complexes such as β-TrCP and Fbw7. 293T cells transfected with various
constructs with DMSO or ZL-25 was treated with MG132 for 6hr followed by in vivo
ubiquitination assay.
The mutagenesis data shows that ZL-25 binds to the Trp97 and Asp98
residues on Skp2, and this compound is specific for Skp2 and no other highly similar
F-box proteins. This prompted a further sequence analysis of the F-box domains of
Skp2 compared to other F-box proteins. When the consensus sequence of all 69
human F-box proteins are analyzed, the ZL-25 binding site occurs in a region of the
F-box where consensus is low (N = 4,5 in below figure), and Skp2 contains residues
not shared by other F-box proteins (Figure 30).
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Figure 30. Consensus sequence of first 31 residues of F-box domain shows ZL-25
binding site in region of low commonality to other proteins (residues 4 and 5 in this
image, corresponding to Trp97 and Asp98, respectively). The consensus is much
higher in the key leucine and proline at residues 7 and 8. Taken from Prosite (260).
There have been other natural products that have been shown to interact with
F-box proteins that show similar structures to ZL-25, (which is structurally an
isoflavone, which is a natural product based on the flavonoid scaffold) although their
specific mechanism of actions and modes/regions of binding have not been
confirmed. 1,2,3,4,6-penta-O-galloyl-β-D-glucose (5GG), curcumin, quercetin as well
as lycopene all cause downregulation of Skp2 protein in two different breast cancer
cell lines, despite the fact that this downregulation did not always correlate with a
corresponding p27 upregulation, but when 5GG is used in combination with chrysin,
tumor growth was suppressed in xenograft mice (261). The isoflavone wogonin was
shown to have anti-cancer effects and was able to down-regulate c-Myc and Skp2 at
the protein level and also FBW7 levels were decreased in A549 cells (262). However,
as wogonin also has potential to inhibit kinases involved in Ras pathways in
melanoma cell lines and has affinity to matrix metalloproteinase-9 (MMP-9) in HCC
(263, 264), it is possible there might be an underlying mechanism of which Skp2 is a
minor player.
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One issue with flavonoids as treatments is that they are readily and easily
metabolized by phase II enzymes such as glucuronosyltransferases (UGTs) and
sulfotransferases (SULTs), reducing their half-life drastically. Isoflavones such as
genistein (ZL-25 is an isoflavone) however have been shown to not be metabolized by
SULT1A3 (the major SULT in humans), but by SULT1A1, which is expressed in
much lower amounts (265). Genistein, when compared to other isoflavone analogs,
has also been shown that the formation of the genistein metabolite did not have
comparable excretion and formation rates, showing that the intestinal disposition of
isoflavone compounds was structurally dependent (266).

2.4.3 In Vitro and In Vivo data of Cks1/Skp2/p27 inhibitor ZM-405
Our collaborators examined the effects of ST029405 (which was renamed to
ZM-405) and found it to be the most active compound. As similar to the initial screen
of ZL-25 via Co-IP of Skp1 and Skp2, this screen used Skp2 and p27. ZM-405 was
able to disrupt p27-Skp2 interactions (specifically, binding to the SCF complex, as
Cks1 accessory protein is required to bind to p27) and inhibit the ubiquitination of
p27. Immunoprecipitated p27 and Normal Ig (NIg) blotted with anti-Ub antibody
show disrupted p27 binding to Skp2 and decreased p27 (Figure 31).
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Figure 31. Initial activity discovery of ZM-405. A. ZM-405 disrupts p27-Skp2
interactions via Co-IP. B. ZM-405 also inhibits p27 ubiquitination. NIg: Normal Ig
To check the specificity of ZM-405, it was tested on a downstream target of
Skp2 E3 ubiquitin ligase, the retinoblastoma member p130, which is another target of
Skp2 (although not as significant as p27) (132). ZM-405 did not disrupt p130 as much
as it did p27 at 10µM doses, indicating it also has good specificity towards its target
of p27 (Figure 32).

Figure 32. ZM-405 does not target p130 for ubiquitination. At 10µM doses, ZM-405
shows it is specific for p27.

88

In light of the knowledge that p27 is only effective when in the nucleus and is
targeted for ubiquitination by Skp2 primarily in the nucleus (after it is phosphorylated
on Thr187 (267) in this study, an attempt was made to look at the endpoint of restore
nuclear p27 localization so that Skp2 and the SCF complex will be inhibited in the
nucleus, and not the cytoplasm. ZL-405 was able, in a dose-dependent manner to
restore nuclear localization of p27 and did not increase cytosolic levels. Again,
consistent with the selectivity that was predicted for targeting the Cks1/Skp2 binding
site, our collaborators found that it had these effects on restoring nuclear p27 while
not having an effect on p130 in the nucleus or in the cytoplasm (Figure 33).

Figure 33. Results of ZM-405 testing on restoring nuclear p27 levels. A. Western
analysis shows selective p27 (but not other targets such as p130) levels increase. B.
Total p27 increase is associated with increased nuclear and decreased cytoplasmic.
Another structural analysis of the Cks1/Skp2 interaction site in comparison to
other F-box proteins shows that the region of Cks1/p27 binding does not share
homology with other proteins, indicating that the specificity of Cks1/p27 binding
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might be due to the differing sequence and explains why p130 is not affected in
inhibitor treatment (Figure 34).

Figure 34. Conservation of residues of seat-belt region of Skp2 (top row) compared
to other F-box proteins. Warmer colors indicate higher conservation.

2.5 Summary of Results and key Conclusions from Hot Spot study and Virtual
Screening Data
After a rigorous study of the structure of Skp2 on two key regions (the
Skp1/Skp2 interface and the Cks1/Skp2/p27 interface), an ensemble of computational
hot spot prediction techniques were used on these two regions and the key residues
that were suggested to be hot spots became the basis on which to perform multiple in
silico high-throughput virtual screens using multiple large datasets of drug-like and
lead-like compound libraries. Two lead compounds were discovered and tested in
various biological systems and found to have good initial activity and good specificity
for different areas of Skp2 (ZL-25 and ZM-405). In the next chapter, multiple
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techniques will be used to analyze their binding and study their effects upon binding
in order to suggest modifications to increase their potency and specificity.
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Chapter 3: Binding Analysis and Pre-Clinical Development of Inhibitors
3.1 Introduction
From the hot spot analysis of Skp2 (both in the Fbox/Skp1 region and the
Cks1/p27 region, we identified two distinct (but yet distant and with differing effects)
regions on which to conduct virtual screens. The subsequent virtual screens gave
compounds that showed biological activity in both regions on Skp2.
Here our aims are to build off of the initial biological results obtained from
both the Skp1/Skp2 and Cks1/Skp2/p27 inhibitors and develop them for future
clinical use. This involves many steps, including: increasing the binding affinity of the
inhibitors to their targets, maintain specificity of inhibitors to the targets, and
minimize off-target effects, evaluate potential overt toxicity events, and maximize
inhibitor’s ability to stay in tumor cells and maximize half-life and minimize
metabolism. A major question that we also hope to answer is how are the inhibitors
binding specifically to their targets, and how are the targets responding to ligand
binding. This is especially important and difficult, as all the inhibitors presented here
are PPIs, so there will be an interplay of not just two elements in the investigation of
the ligand binding.
A concern with the Skp1/Skp2 inhibitor (ZL-25) is that, as was confirmed by
the mutagenesis, it binds to Trp97 and Asp98, which are residues that are two away
from the end of the Skp2 crystal structure in the 2AST PDB entry (242). The concern
here is that the remaining 95 residues on the N-terminus tail of Skp2 very well might
be significant for our study of ZL-25 binding, and certainly the N-terminal tail of
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Skp2 must have significant interactions with Skp1 as well. Indeed, it was shown,
when a mutant Skp2 was created without the 95 residue tail, the in vitro binding to
Skp1 was greatly enhanced (data not shown), therefore it also must be oriented in
such a way that would prevent its binding. Additionally, the nuclear localization
signal is a motif in the region of residues 67-73.
Therefore, to address this concern, before conducting binding analysis, a
homology model was built that recreated the 95 residue N-terminal tail of Skp2.
Homology modeling is a method that is well established and has been documented
widely(268), and it is based on the assumption that proteins that possess similar
sequences must also share similar three dimensional structures, and the number of
protein folds that exist in nature must be relatively limited (269, 270). This technique
has been widely utilized by many drug discovery which are based on the structural
elements of the protein and has been proclaimed as the best prediction method of
structural homologous protein (271).

3.2 Materials and Methods: Development and Application
Multiple in silico techniques are discussed here that are widely used to
streamline and rationalize drug discovery efforts and aid in decisions of the drug
discovery pipeline. Briefly they will be introduced before the specifics of the
materials and methods are mentioned below.
Homology modeling involves the generation of a novel structure based on two
primary elements: the sequence of a target protein and the model of an existing
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structure with a similar sequence. It is widely used when x-ray or NMR structures are
not available of certain protein but other family/species member proteins are
available. Molecular dynamics (MD) simulations is an all-atom computer simulation
of a system to study the physical movements of systems of atoms. Usually the atoms
have their forces and potential energies modeled in a trajectory and the system is
allowed to progress in small movements and the energies and potentials (force fields)
are re-evaluated after each step. Both these programs are widely used in
computational drug discovery efforts (268, 272).
This is a computationally expensive process, to simulations were carried out
via the Texas Advanced Computing Cluster (TACC) in Austin. In order to determine
what settings would yield the best performance on the TACC, a series of identical
jobs were run to determine the optimal number of CPUs and nodes to utilize that
would provide the longest simulation in a 24 hour time period (Table 11. Influence of
Number of CPUs utilized on length of MD simulation).

Number of Nodes

Number of CPUs

Length of 24hr simulation

Utilized on TACC

Utilized on TACC

(picoseconds)

1

144

36590

2

288

9649

10

1440

886

11.6

1680

831

Table 11. Influence of Number of CPUs utilized on length of MD simulation
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Here we can see that the cross-talk between even just two nodes is a limiting
factor, and therefore 144 CPUs is the optimal environment for this system to yield the
best results before the simulation reaches the 24 hour wall time in the TACC
environment.

3.2.1 Skp2 N-terminal Tail Homology Modeling
The initial coordinates of Skp2 was obtained from the Protein Data Bank
(PDB code: 2AST) (239). The Skp2 N-terminal tail used PDB code 2OVP (273) as
the template, which is based on FBXW7, a similar F-box protein. This structure has
not the entire tail, but residues 65-95. Additionally, when these structures are aligned,
the extra residues on 2OVP form a well-structured helix behind the H2 and H3 helixes
of the F-box domain of Skp2. The alignment was performed using the UCSD Biology
Workbench with the default parameters, and MODELLER (version 9.17) was used to
build the homology model (274) and perform loop refinement. 10 models were
generated and evaluated based on their molpdf and DOPE scores as well as refined
and validated visually (no obvious structural clashes/error).

3.2.2 SCF Complex Homology Modeling
Similar to the N-terminal tail modeling, the initial coordinates of the SCF
complex was obtained from the Protein Data Bank (PDB codes: 2AST, 1LDK)(242,
245). The gaps that are missing are as follows: Cul1 is missing the N-terminal
residues 1-16, a large loop region with residues 55-84, and a second loop region
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between residues 148-157. For Skp1, a loop is missing between residues 70-91.
Finally, and again similar to the above modeling, the Skp2 N-terminal tail used PDB
code 2OVP (273) as the template, which is based on FBXW7. This structure has not
the entire tail, but residues 65-95. The residues were added based on the H. sapiens
Skp1, Skp2, and Cul1 sequence (Uniprot IDs: P63208, Q13309, and Q13616,
respectively. MODELLER (v. 9.17) was used to generate templates, and the best
models were selected based on molpdf DOPE scores. 10 models were generated for
each “run” and 10 runs were created, resulting in 100 overall models. From each run,
a different random seed was selected to ensure that each run was independent of the
previous ones. They were then inspected for obvious clashes/errors/improper angles.
The top 2-3 candidates from each run were selected that had both the best molpdf
DOPE scores and did not have any improper chains being inserted inappropriately
into other elements of the SCF complex (e.g. MODELLER occasionally inserted the
N-terminal loop region of Cul1 in between the H2 and H3 helixes of Skp2). These top
2-3 models from 10 runs were then compared and the top model was selected.

3.2.3 Skp2 Mutants Molecular Dynamics
The 2AST structure was used and stripped of all non-Skp2 atoms (Skp1, Cks1,
p27, waters, and benzamidine groups. Three structures were generated: Wild type (no
changes), a Trp97Ala mutant, and an Asp98Ala mutant. PyMOL was used to perform
the mutations, and MOE performed a small minimization step on the side chain to
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relax the mutants. AMBER software package was used as the software for the MD
and the analysis (275).

3.2.4 Skp2 N-terminal Tail and the SCF Complex Molecular Dynamics
All molecular dynamics simulations were performed by the AMBER14 software
package(275). For Skp1-Skp2, Skp2, Skp2-ZL-25 simulations, the 2AST structure
was again selected. For the complete SCF complex with loop and tail regions, the
model from the work done in the above section was used. The ff14SB force field
(276) was induced to outline the atomic interactions between the protein elements.
Structures were inserted in the centroid of a cubic water box using TIP3P (277). The
system was energy minimized using steepest descent algorithm. After minimization
step, the system was heated with water at 300K, and a density step was performed.
After the density step, the production simulation was submitted. MMPBSA was used
to analyze the energy of the ligand binding. RMSD and other AMBER analysis and
processing of results was performed by the PTRAJ and CPPTRAJ packages (278).
All simulations were performed remotely on the Lonestar HPC cluster at the Texas
Advanced Computing Center (TACC) in the University of Texas at Austin.

3.2.5 Cks1/Skp2/p27 interface Molecular Dynamics
The 2AST structure was used, but only Skp1, p27 and the benzamidine groups
were removed, keeping Cks1 and Skp2. All other settings used were same as previous
MD runs described above.
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3.3 Structure Activity Relationship (SAR) Results
Next, a search was conducted for both lead ligands to find compounds with the
same core scaffold, but had small modifications to uncover changes that would lead to
better activity, namely, a structure activity relationship (SAR). A similarity search
was carried out on each lead structure in the PubChem chemical database (279)
(starting with 95% similarity) and structures that were commercially available were
selected.

3.3.1 SAR results of ZL-25
For ZL-25, 14 structures were found and tested first as an in vitro Skp1-Skp2
binding assay similar to the primary assay used to discover ZL-25’s activity (Figure
35).
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Figure 35. Structure-activity relationship (SAR) of ZL-25 and its derivatives. #25-5 is
illustrated separately due to its unique core structure.
The testing of these 14 revealed only two compounds with similar activity to
the lead, listed as 25-5 and 25-9 (Figure 36). These were also tested in an in vivo
ubiquitination assay and a multi-dose cell survival assay, and these two also
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performed just as well as the lead, but not significantly better than the lead compound
(Figure 37).

Figure 36. In vitro Skp2-Skp1 binding assay in the presence of DMSO, ZL-25, or its
derivatives. Only 25-5 and 25-9 were as active as the lead, ZL-25.

Figure 37. 25-5 and 25-9 results matched lead, but no better. 293T p27 ubiquitination
assay with various constructs in the presence of DMSO or ZL-25 (Left). PC3 cells
with various doses of ZL-25 or three other derivatives (25-6 is less effective) (Right).

Even though there were only two active compounds, the inactive compounds
tell us about the structural features that are required and not required. Looking at
Figure 35 at the chromone core structure and consider the different R groups, at the R0
position the benzothiazole group (upper right side) seems needed; the 25-13 and 2514 4-Me-thiazole lost their activity. The double ringed benzomidazole (25-9) and
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benzothiazole (all other compounds) groups are very similar and are able to more
readily form pi-stacking interactions with Trp97 on Skp2. This also matches what we
know about the mutagenesis efforts on the Trp97 group.
On the R1 group (upper left), the ethyl group possibly is required, but at the
same time 25-5, (that has a chromen-2-one core), was able to bind without an ethyl
group, but this might be due to the hydroxyl group’s interaction with the
benzothiazole group in forcing it to not lie perpendicular to the chromen-2-one group.
This also can be considered viable when one compares the structures with methyl or
other large groups in the R2 position (25-12, 25-10, 25-6, 25-2, and 25-3). The R3
position appears to benefit from a large ring group.
There have been additional rounds of SAR testing were carried out by three
different sets of collaborators (the second round had 12 compounds, the third round
had 11 compounds, the last one had six) and unfortunately the results often conflict
with the previous group’s work. The second round of testing used a similar pull-down
assay to what was used in the first assay, but most of these results were inconsistent
with the first round of testing. Additionally, compounds that appeared to perform well
actually failed in secondary screens. However, the one conclusion that was definitive
across both SAR tests is that a large R3 group is required and cannot be hydrogen
while there is no large group also on the 7’ position (where the hydroxyl group lies on
ZL-25).
The results are shown below, all the tested compounds from the first two SAR
studies were docked using three different scoring functions and the molecular weight
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and logP displayed. The values are color coded relative to all the others. More
favorable values are greener and less red. The column “Norm. w/ vehicle” indicates
the activity in two ways: either a percentage value showing % of Skp2 binding to
Skp1 (lower number is better), or a value of 5 through 1. This is a scoring system that
was used to rank the ligands. Five is comparable to ZL-25, 4 is about 50% as good, 3
is even less as active as a 4 and was inconsistent in activity (experiments were
performed in duplicate), 2 is even lower and inconsistent, and a value of 1 had
absolutely no effect (Table 12).
Gold
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Table 12. Combined results of first two SAR studies. Values are color coded to have
more favorable values in green. 5: comparable to ZL-25, 4 is about 50% as good, 3 is
even less as active as a 4 and was inconsistent in activity (experiments were
performed in duplicate), 2 is even lower and inconsistent, and a value of 1 had
absolutely no effect.

The third round of SAR testing was a viability assay and actually used ZL-25
from two different vendors. The far right lane (#25) is ZL-25 from a primary vendor,
#7 is from a secondary vendor and appeared to have slightly different activities. Two
compounds were repeated across the two studies from the first round of SAR testing
(data from Figure 35) and were consistently inactive: #6 is 25-5 from the previous
study, as is #10 identical to 25-10. #12 is 25-13 from the previous study (Figure 38).
Compounds from this study are in (Figure 39).
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Figure 38. Second SAR study comparing viability. #7 is a batch of ZL-25 from a
newer vendor, #25 is ZL-25 from a more previous vendor. Structures are visible
inFigure 39.
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Figure 39. Compounds used in 2nd SAR study (results on Figure 38).

Compiling the results of all three group’s work into one table has been
performed, and the best understanding of the compilation of the work is presented
here (Figure 40).
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Figure 40. Compilation consensus of conclusions of all SAR studies. On a perposition basis.

3.3.2 SAR results of ZM-405
ZM-405 has only had one primary SAR study, with only three compounds
with one change on the benzene ring resulting in any activity (R3 group) (Figure 41).
The hits were tested in ECC1 cells for 24hrs with shown doses and after 24hrs, total
protein levels were determined by western with specific antibodies and it was
determined that 9276 and 8243 were considered better performers than ZM-405
(Figure 42). A new compound (which has its info redacted) became then the new lead
compound candidate for this project and was renamed ZM-276.
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Figure 41. SAR study of ZL-405 inhibitor. #2 (redacted) was shown to be more
effective than ZL-405. Modifications to R3 group highlighted.

Figure 42. ECC1 cells treated with 3 ZM-405 analogs (last three digits indicate IDs).
243 (redacted) and 276 (redacted) performed better than ZM-405.

An additional 76 compounds were selected with high similarity to ZM-405
and were tested in a high-throughput assay for their ability to restore nuclear p27
levels. Unfortunately only the compounds with modifications on the R3 group were
active. There was great sensitivity on this group, and even other aromatic rings were
completely inactive when compared to groups with large bulky modifications at the
end of the R3 ring (Figure 43).
111

Figure 43. ZM-276 (left, redacted) was highly active in restoring nuclear p27, but
SKT823113 (right) was almost completely inactive.

3.4 Homology Modeling of Skp2 N-terminus Tail Results
The original discovery of ZL-25 used the 2AST structure and the virtual
screening took place on two regions of the Skp1/Skp2 interface. Originally, this
project was to examine only the interaction between Skp2 and the ZL-25 ligand,
perhaps taking into account Skp1 to explore the ligand binding and aid in the
enhancement of the binding and efficacy of ZL-25. The ligand binding region of ZL25 occurs on Trp97 and Asp98, and this site exists only two residues before the Nterminus end of the Skp2 2AST structure (Val95) and the rest of the N-terminal tail is
unresolved.
As was said previously, the missing residues of the N-terminal tail have not
been crystalized before the Val95 residue, and none have been described to have any
known secondary structure using any method currently available. Using various
prediction tools indicated that there might be some small secondary features. For
example, PsiPred indicated that there is a small helix from residues 40-43 and a larger
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one from residues 52-58, and a very small coil in 80-83, but the confidence in this coil
is very low (Figure 44).

Figure 44. PsiPred prediction of secondary structure of Skp2 N-terminal tail. 2AST
structure starts at residue 95.

The most adequate of an F-box protein template that was found to have the Fbox domain and a longest region of the N-terminal tail was the 2OVP protein from
Fbw7 (or FBXW7). This F-box protein had its additional 15-residue N-terminal tail
existing both in a 2.5 turn (9 residue) helix and in a region closer to the LRR domain,
and residing behind the H3 helix of Skp2, forming hydrophobic bonds between this
tail and the Skp2 H3 helix (Figure 45). This 2OVP structure was initially used as the
template on which to model a 15-residue extension of the N-terminal tail of Skp2.
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Figure 45. Modeling of Skp2 N-terminal tail. 2AST structure (green) compared to
2OVP structure (blue). 2OVP has additional residues crystalized and shown a position
behind H3 helix.

Five final tail models were selected based on their molpdf and DOPE scores,
and each were diverse in their final positions relative to Skp2 (this was not a selection
criteria). They were called mod6, mod9, mod11, mod18, and mod20 (colored yellow,
light blue, red, and purple, respectively in Figure 46). The highest scoring model was
in fact mod11 (Brown structure in Figure 46), which adopted a configuration in
which the N-terminal tail occupied the ZL-25 binding site and forms extensive
contacts in between the H1 and H2 helixes of the Skp2 F-box which is the primary
binding site of both Skp1 and the Skp1-Skp2 inhibitor ZL-25). This mod11
conformation might indicate that when a Skp2 N-terminal truncated mutant is
114

compared to WT Skp2, the mutant forms in the SCF complex almost 50% faster (data
not shown).

Figure 46. Highest scoring homology models of Skp2 tail. Four models showed on
left have diverse structures (left). Mod11 (brown) is the only model that occupies
Skp1 and ZL-25 binding site between H1 and H2 helixes (right).

3.5 Homology Modeling of SCF Complex Results
After further investigation into the entire SCF complex, it was determined that
loop regions of Skp1 and Cul1 would have to be considered when modeling the Nterminal tail of Skp2, and other structures were added to the 2AST structure. The full
model of the SCF complex revealed that the 2OVP structure is in fact inappropriate
for the N-terminal tail model, as it lies in a region which is occupied by Cul1 and
clashes with multiple parts of this large protein (Figure 47).
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Figure 47. Skp2 (green) with Cul1 structure (purple) shows large regions of steric
clashes (red). Using the 2OVP template of the F-box protein, this model cannot adopt
a conformation into the SCF complex without clashing with Cul1 residues.

3.5.1 Active Recruitment Modeling of SCF Elements.
It has been understood that there are post-translational events that occur in on
the SCF complex that facilitate the recruitment of its constituents to the SCF complex.
In order to help understand how these events impact Skp2 recruitment, they were
recreated in the current SCF model. It was recently discovered that the Ser256
residues in the LRR domain of Skp2 is important for Skp1 and Cul1 binding.
(Ironically, SCFSkp2, after Akt phosphorylation, binds to FOXO1 and induces its
ubiquitination at the same residue on FOXO1, Ser256 (280)). This Ser256 on Skp2 is
located at the end of the 4th leucine-rich repeat (LRR4) opposite the side of where
Cks1 binds and is oriented in a way that its side chain is pointing towards Cul1(Fig5).
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This would indicate that, if Skp2 was able to “bend” towards Cul1, it would
potentially interact with corresponding residues on Cul1. Merging the 2AST and
1LDK structures, the Ser256 residue on Skp2 is closest to Asp216 and Leu225 on
Cul1, with distances of 19.4Å and 26.4Å, respectively, requiring only a 31.7° bend in
the Skp2 F-box domain in order to come within the distance where these residues
could form extensive interactions. The 10 residue loop region that was generated
between Asp216 and Leu225 (DDAFAKGPTL) by MODELLER extends the loop
towards Skp2 and the Ser356 residue. The most notable residue of this loop region is
Lys221 in the middle, which extends its side chain even closer to Skp2.

Figure 48. Active recruitment of SCF complex members is enhanced by
phosphorylation of key residues. Ser256 on Skp2 results in its enhancement of
formation of the SCF complex. Modeling of a key loop region on Cul1 shows that
Lys221 on Cul1 can bind to Skp2 when the F-box domain bends only 31.7° (blue
cartoon). The Cul1 Lys221A mutant displays similar rates of complex formation to a
Skp2 Ser256A mutant.
When tested biologically, both residues are shown to impact the assembly of
the SCF complex; mutation of Lys221 on Cul1 results in a SCF complex that is at
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least 50% slower to assemble, and this mutation is similar to a Ser256 mutation on
Skp2.
In terms of the post-translational modifications that result in active recruitment
of the SCF complex, there have been multiple previous reports to this regard beyond
those that take place on Skp2. For example, p27 is required to be ubiquitinated at the
Thr187 and Ser10 residues (281). In Toxoplasma gondii, Skp1 has been shown to be
glycosylated by five glycosyltransferases encoded by three genes on the Pro154
residue in an evolutionarily conserved pathway that results in a pentasaccharide at this
Pro residue (282). This residue corresponds to Glu147 in humans. The assembly of
the Skp1/F-box protein heterodimer is shown to be more efficient when this
glycosylation is present, based on interactome studies (283). The SCF model
presented here shows that this residue is not only solvent exposed, but in a structural
position completely unprotected in relation to the other elements in the SCF complex
(Figure 49). Additionally, all Cullin proteins (including Cul1) have been found to be
neddylated by the ubiquitin-like protein Nedd8/Rub1 and gave the first clue as to how
these large proteins are regulated(284). In regards to the Cul1 protein specifically, it
has been shown to be neddylated by Nedd8 on K720 in its winged-helix B (WH-B)
domain (although the authors report the residue as K696), which results in enhanced
activity towards p27 (285, 286). To remove the Nedd8 protein, the signalosome
protein COP9 signalosome (CSN) is required, and this allows the binding of
paralogous regulatory factor proteins called Cand1 and Cand2(287). When Cand1
binds to Cul1, it results in a disruption of the F-box protein to bind to the Skp1 protein
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and results in the inhibition of the conjugation of Nedd8(288). Additionally, Rbx1
(another critical component of functional SCF ubiquitination) is found to be necessary
to require neddylation and also enhances the E3 ligase activity of the SCF complex.
This is partially explained by the fact that the location of K720 on Cul1 is proximal to
Rbx1 in the 1U6G structure (only 5.6Å away).

Figure 49. Post-translational events on other elements in SCF complex. A. Glu147 on
Skp1 is glycosylated to enhance the binding of Skp1 to the SCF complex.
The complete model of the SCF complex with the Skp2 tail and all loop
regions reveals the complexity of the system and potential interplay among the
elements and their resulting biological aspects (Figure 50). The first 16 residues of
the N-terminal region of Cul1 have the potential to interact both with Skp1, and with
the ZL-25 binding site on the interface between Skp1 and Skp2. The large 30 residue
loop (Ser55 through Val84) is even closer to Skp1/Skp2 (including the LRR regions
of Skp2) and has an even higher potential of interacting with the ZL-25 binding site.
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Figure 50. Generation of full model of SCF complex. Using Modeller9.17, a
homology model was generated that includes missing residues of Skp2 N-terminal
region (green), Skp1 including missing loops (blue), and missing N-terminus/loops of
Cul1 (magenta). Additionally, the ZL-25 ligand was added in its docked pose (green
sticks).

3.6 Molecular Dynamics of Skp2 Mutants Results
Simulation of the Skp2 protein over a long period of time (182ns) shows the
relative stability of its different regions (Figure 51). The F-box domain is highly
destabilized compared to the highly stable LRR region, and, surprisingly, the seatbelt
region that extends from the end of the 10th LRR and loops back to the F-box domain
shown a higher stability difference than the F-box domain.
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Figure 51. RMSD of backbone atoms from molecular dynamics simulations across
182ns of Skp2 with a 15 residue N-terminal tail of various portions of Skp2
represented. N-terminal tail and F-box show greatest amounts of variability, whereas
the LRR and seatbelt regions are the most stable. The region in between the F-box and
the LRR domain is very stable but has the potential to become destabilized for a short
period of time.

Simulations of WT Skp2 in comparison with R126A and W127A mutants
support the known biological information of these isoforms. It has been shown that
the R126A mutant loses its ability to bind to Skp1 in the F-box domain, whereas the
W12A mutant is able to retain its binding to Skp1 (176). When RMSD plots are
generated for these three isoforms of the F-box domain, the WT and W127A isoforms
show similar results, where the R126A mutant shows a significantly higher F-box
backbone destabilization relative to the other two (Figure 52).
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Figure 52. RMSD backbone plots of MD simulations of F-box domains of 3 different
Skp2 proteins. (Top graph): 3 different simulations were carried out of Skp2: Wildtype (blue), W127A mutant (green), and R126A mutant (red). (Bottom): Average and
standard deviation bar chart plot of the same data.

Upon closer examination of the F-box domains of these mutants, the H3 helix
is the most shifted during this simulation, pulling apart the H1 and H2 helixes. Also,
at times the seat belt region (the final residues of Skp2 that have folded back from the
LRR domain), have a greater interaction with the end of the H3 helix.
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3.7 Molecular Dynamics of Skp2 of SCF Complex Results
It has been widely understood that the flexibility of Skp2 occurs largely in its
F-box domain, and in the linker region between the F-box and the first LRR region.
This is flexibility is proven to be present upon examining MD simulations as well
(Figure 53). This flexibility explains how it is reasonable to see how Skp2 and Cul1
can interact via a phosphorylated Ser256 residue on Skp2. In fact, only a 31.5°
movement of the “hinge” region between the F-box domain and the first LRR region
of Skp2 moves Ser256 to within 7.3Å of Lys221 on Cul1. This rotation is certainly
possible, as two other structures of Skp2, 1FQV and 1FS2, have a rotation angle in the
same area of 61.6°. A small rotation of the side chain on Lys221 brings it within
hydrogen bonding distance of Ser256 on Skp2. This movement in Skp2 is seen
primarily in three residues: Ser135, Leu136, and Trp137, which lie just after the H3
helix of the F-box and the first LRR region. This region is also able to move more
freely as it is not significantly stabilized by the “seat-belt” region of Skp2 (residues
415-419).

123

Figure 53. 11 superimposed snapshots of Skp2 after 182ns simulations. The
simulation shows very little movement in the LRR and ‘seatbelt’ region (upper
portion), whereas the F-box domain shows significant levels of dynamics (lower
portion).
There exist many post-translational modifications that are highly relevant for
Skp2 that help us to understand the results presented here. The 95 residue N-terminal
tail of Skp2 just before the F-box domain (also known as the nuclear localization
signal, or NLS) is especially biologically highly significant for multiple reasons. The
NLS lies within this N-terminal region, and Skp2 is acetylated at K68 and K71 by
p300 (289). This acetylation stabilizes Skp2 via impairment of Cdh1-mediated
proteolysis pathway, as well as promotes cytoplasmic retention. Multiple studies have
shown that Akt binds to Skp2 in the N-terminal region (The substrate motif sequence
of Akt is RXRXX(S/T), where X is any amino acid (290)), phosphorylating Skp2 on
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Ser72 in a manner comparable to that of TSC2, a well-known Akt substrate. Other
kinases (Akt2, SGK, or S6K) do not do this (214, 291, 292). It is understood that this
event triggers SCF complex formation, E3 ligase activity, and triggered 14-3-3βdependent Skp2 cytosolic relocalization (291). It is worth mentioning that subsequent
studies found information to the contrary; Ser72 phosphorylation does not control
Skp2 binding to Skp1 and Cul1, does not influence SCF ubiquitin ligase activity with
Skp2, and has no affect Skp2’s subcellular localization (293, 294). Therefore, when
considering the effects of ZL-25 binding in the context of Skp2, one not only should
consider the other elements of the SCF complex, but: the post-translational events that
readily occur, the events that occasionally occur, and the resulting biological and
structural implications of the interactions of these post-translational events in the
context of all of the SCF complex.

3.8 Molecular Dynamics of N-terminal tail Results
The Skp2 N-terminal tail has been shown to have a high level of flexibility,
but the other elements of the SCF limit the available space of the tail. When Skp1
binds to Skp2, the tail loses about 20% of its available inhabitable region (if we
assume that it has complete freedom compared to the Skp1/Skp2 complex vs Skp2
alone). We know that, when tested biologically, the removal of the Skp2 tail greatly
enhances the assembly of the SCF complex, so it is safe to assume that the N-terminal
Skp2 tail can be in conformations where it prevents at least one of the other SCF
members from binding. This is evident when we examine 4 snapshots of 1 simulation
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of mod20 (one of the best performing tail models from the homology modeling of the
tail residues of Skp2) over the course of 80ns. As the model progresses, it occupies 4
very unique positions with roughly the same secondary structure throughout. It is
worth noting that this is not the full length tail of Skp2; it is only an extra 20 residues
and not the full 95 residues (Figure 54).

Figure 54. Four snapshots of MD of Skp2 model with N-terminal tail portion. 4
snapshots taken 20ns apart show very unique positions of the tail. Trp97 (green sticks)
showing original 2AST structure.

However, the addition of the much larger Cul1 (making a Skp1/Skp2/Cul1
complex) restricts the position of the Skp2 N-terminal tail in a much more significant
manner; it basically now has two primary positions that are 180°apart: one where the
tail is extended away from the LRR domain of Skp2 (and away from the Cks1/p27
binding site) and is highly solvent exposed, or one where it extends in the complete
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opposite direction towards the LRR domain of Skp2 (these two configurations will be
referred to henceforth as simply exposed and buried).
The evidence that the exposed conformation is the most likely is to be found in
the high number of post-translational events that occur on the N-terminal tail that
require it to be solvent exposed. Akt1 (but not other kinases such as Akt2, SGK or
S6k (214)) phosphorylate Skp2 on Ser72 (214, 291). Another study showed that the
Ser72 phosphorylation event creates a priming site on Skp2 for subsequent
phosphorylation by Casein Kinase I (CKI) on Ser75 which was detected by a cancer
cell phosphoproteome (295). When both Ser72 and Ser75 are phosphorylated,
association with Cdh1 is impaired, thus permitting Skp2 to avoid APC/Cdh1mediated ubiquitination and destruction(296). This is significant, as Skp2 itself is
degraded via the APC/Cdh1 ubiquitin ligase, and binds to the N-terminal domain of
Skp2 on residues 46-94.One notable neighboring phosphorylation site to Ser72 also
with notable effects is Ser64 (214). Interestingly, this site is the most conserved site
phylogenetically within the region of Cdh1 binding and is found in all Skp2
orthologues, from vertebrates to insects, and also notable is the fact that this
phosphorylation site is always located about 30 residues N-terminal to the F-box
(292). One study found that mTORC1 also functions to regulate Skp2 by Ser64
phosphorylation and this actually has the potential to represent an oncogenic event in
gastric cancer, as the combination of p-Skp2 and p-mTOR (phosphorylation of
mTOR) expression was a better predictor of survival than either factor alone (297).
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Another recent discovery of the N-terminal tail of Skp2 is its inclusion of a
“destruction box” (D-box) motif. The core sequence of this motif is an arginine
followed by two residues, then ending in a leucine (RXXLXXXXN/D/E) (298),
which starts on Arg84 on Skp2 and ends on residue 92. Proteins with a D-box have
been shown to interact with another ubiquitin-protein ligase called the anaphasepromoting complex or cyclosome (APC/C), and the first 90 residues of Skp2 are
required for Skp2 degradation by APC/C in the G1 phase (299). This D-box domain
on Skp2 is very close to the start of the F-box domain (residue 94). Considering all of
these post-translational events and other protein elements that bind to the N-terminal
tail of Skp2, it is highly unlikely that all these modifications and events occur when
Skp2 is not bound to other SCF complex members or buried inside its other SCF
partners. These facts indicate that the exposed form of the Skp2 N-terminal tail is the
most likely conformation to exist biologically.

3.9 Molecular Dynamics of ZL-25 Binding Results
Simulations of the Skp1/Skp2 complex with the loop regions added to both
proteins and with ZL-25 docked were performed. The regions that showed the
greatest displacement were the two final helixes on the C-terminus of Skp1, and
surprisingly the F-box domain of Skp2 showed only minor movements (Figure 55).
Also interesting, was that ZL-25 actually flipped the relative locations of the
benzothiazole group and the chromone core compared to the original starting docked
structure at the relative start of the simulation, at about 16ns into a 32ns simulation.
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This rotation was seen on at least 2 separate simulations (Figure 56). This is actually
still reasonable, as the chromone core still has aromaticity and can still form pistacking with Trp97 (albeit not as strong as the benzothiazole group), and the Asp98
residue can potentially interact with the benzothiazole group.

Figure 55. Results of MD simulation of ZL-25/Skp2 complex A. Backbone RMSD
(blue) of Skp1/Skp2 in complex with ZL-25 of a 140ns simulation. B. RMSD colorcoded comparison of starting structure with final structure. Color goes from blue
(small/no displacements) to red/grey (large displacements). ZL-25 shows a rotation
across an axis perpendicular to main axis of Skp1/Skp2 structure.
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Figure 56. Molecular Dynamics simulations of ZL-25 ligand in complete SCF
complex with Skp2 N-terminal tail. From the starting structure (green), ZL-25 rotates
its orientation relative to the starting structure after approximately 16ns (magenta).
The average RMSD from the starting structure (Skp1/Skp2/ZL-25) to the end
of the 140.3ns run was 2.95Å, but the maximum distance was 10.21Å. Additionally,
comparing the per-residue RMSD of both the bound and unbound forms of Skp2 with
ZL-25 show a destabilization in the F-box domain, whereas the other regions of Skp2
remain basically unchanged (Figure 57).
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Figure 57. Average RMSD per-residue of Skp2 in both bound (blue) and un-bound
(red) states. Residues Asp373 and Asn403 are in highly variable regions of Skp2 Fbox shows highest destabilization effects upon ligand binding. Asp373 and Asn403
mark the end of the LLR domain, and the middle of the seat-belt region, respectively.
This F-box destabilization is also indicated in the Ramachandran plots of the
bound and unbound forms after a 42ns MD simulation. The majority of the residues
that show changes in their dihedral angles lie in the F-box domain and there are in fact
more than three times as many in the bound form vs the unbound state (7 vs. 25). The
two major improper angles (red residues) in the starting structure and the lone
improper angle in the bound form are either residues on the edges of the LRR domain,
the end of the LRR transitioning into the seatbelt, or in the middle of the seat belt;
residues that are highly solvent exposed or in regions where high torsion will
naturally exist (Figure 58).
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Figure 58. Ramachandran plot of (A) unbound and (B) bound forms of Skp2 with
ZL-25 ligand after 42ns MD simulation. The majority of the shifted angles are from
the F-box domain.
It has been estimated that 85% of proteins undergo conformational changes
upon binding to a ligand, and these changes can range from a simple rotamers (300)
of key binding site residues to larger domain rearrangements (301). As ZL-25 is a
protein-protein interaction disruptor, the results from the MD simulations here show
that this inhibitor can destabilize Skp2 in its F-box domain in a manner that results in
its ability to prevent its binding to Skp1. As Skp2 is the rate-limiting component of
the SCF complex, its inability to bind to Skp1 results in a loss of ubiquitination
activity for its ligands such as p27.
To summarize, in this section, we used homology modeling and molecular
dynamics simulations to indicate that the intricacies of the SCF complex are not
confined to just one protein and there are also post-translational events that must be
considered when selecting models and evaluating results from these studies.
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Chapter 4: Summary and Future Directions
4.1 Summary of Hot Spots and their role in Drug Development
This study offers significant evidence that hot spot residue analysis offers the
potential to expand the drug-target space by allowing researchers to examine PPIs as
potential targets. PPIs have been proposed to be good candidates for drug targets, and
notable cases include examples such as iNOS, LFA-1 and 14-3-3 pathways (302).
Targeting PPIs have unique drug discovery challenges that will need to be overcome
if they are to become a viable alternative to targeting enzymes or receptors like
GPCRs. Standardized enzymatic turnover or kinetics can often not be used for some
PPIs as a surrogate for the potency of hits, so design and execution of proper assays to
measure responses that fit the proposed mechanism must be carried out. Also,
accurate prediction as to how PPI disruptors/inhibitors alter the pathobiology and
function of target proteins will be more difficult than enzyme/receptor predictions, as
these traditional targets commonly have distinct residues/regions that are catalytic in
nature and can be focused upon(303). Finally, proper library design must be utilized
and as more PPI disruptors/inhibitors are uncovered, perhaps pharmacophores or
moieties will be uncovered that are more likely to lead to their activity in certain
features of PPIs.
Alanine scanning mutagenesis, while costly and time consuming, can be
carried out using the prediction tools carried out here, but care must be given as to the
potential biases or weaknesses of each prediction method. When possible, ensemble
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methods as well as simple structural analysis should be used to supplement these
techniques to minimize false positives and false negatives.
The theory and practice of using small molecule inhibitors to disrupt proteinprotein interactions of protein complexes is a novel one, and one that will require
further exploration of the dynamics of proteins involved. While still in its relative
infancy, proposed procedures and strategies have been outlined for using hot spots
towards developing small molecule inhibitors of PPIs (304). This exploration is aided
by the use of computational tools such as homology modeling and molecular
dynamics. Advances in in silico high-throughput screening are also needed to identify
active compounds and will speed the process of identifying hits. Multiple groups in
both industry and academia are making use of high-performance clusters (HPCs, also
called grid or distributed computing) that use multiple networked computers that can
be set to perform intensive calculations (most notable are MD simulations and in
silico virtual screens).
Also of significance to the advancement of this field is the ever-increasing
computing power and capacity of individual computers in both hardware and
software. As computational speeds increase and molecular dynamics simulations
increasingly become optimized in their scoring function accuracy and speed to take
advantage of elements such as parallel computing and utilization of both nextgeneration graphical processing units (GPUs) and CPU architecture(305), these
simulations can be performed on timescales that will allow for the visualization and
analysis of studies such as large, multi-subunit domain movements, assembly of large
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protein complexes, and protein-ligand interactions such as the ones presented here,
even the potential of simulations heading into the second timescale (as opposed to
nanosecond or millisecond) are predicted to be capable based on current trends by the
year 2022 (306-308)
Hence, we believe that a well-developed structure-based modeling technique
designed specifically for PPIs, e.g., structure-based virtual screening, is still in its
infancy but holds the potential for increasing the drug-target space for cancer and can
potentially be expanded towards other diseases.

4.2 Skp2 and the Ubiquitin pathway as a Potential Clinical Target
Skp2 is a prime target for further development as a cancer target, as it clearly
shows over expression (and not mutation or truncation/deletion) in multiple cancer
types. Compared to bortezomib, the general proteasome inhibitor, targeting the E3
ligase allows for tighter specificity and selectivity with less associated toxicity. There
exist multiple endpoints for targeting the ubiquitin pathway, and this study gives
strong evidence that there exist multiple mechanisms by which disruption of the SCF
complex can be achieved: targeting the large interface of the Skp1/Skp2 interaction in
the F-box domain of Skp2, as well as targeting the p27 binding site on the Cks1/Skp2
interface. As we have shown with the inhibitors presented here, this specificity and
selectivity can be achieve; other highly similar F-box proteins were not active towards
ZL-25 (276 has not been tested against similar proteins at this time). As has been
discussed previously, only two compounds (Lenalidomide and Pamalidomide) that
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target elements of the ubiquitin pathway have been FDA approved (excluding the
proteasome inhibitors). When one considers that there are approximately 40 E2
(ubiquitin-conjugating enzymes) and over 600 E3 enzymes in humans (309), clearly
there exist multiple opportunities to utilize PPI disruption (especially when
considering hot spots) to rationally design small molecules to other elements of the
ubiquitin pathway (Figure 59).

Figure 59. Potential strategies for targeting the ubiquitin/proteasome pathway. This
study presents two strategies for targeting the E3 ligase system of SCF/Skp2 (green).
To look for other potential projects on which small molecules could be
designed for small molecule inhibition similar to the two studies that were performed
on the two regions of Skp2, a literature and structure search was carried out for all
other E3 ligase proteins, there exist a few potential targets that should be considered
(Table 13). Most notable is FBXL10 and FBXW7, both have evidence of pathology
to cancer, and have structures available. Some candidates do not currently have
crystal structures available; for these either homology models could be built, or as
crystallographers improve, these structures might be resolved at a later date.
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Table 13. Potential F-box protein targets for future examination of small molecule
inhibition.

The stabilization/restoration of p27 appears to be the driving force behind the
effectiveness of both SCF complex inhibitors, and this has been demonstrated
previously to be effective and achieved by other methods. One study has revealed two
significant findings about dasatinib: first, that it enhances paclitaxel-associated
apoptosis by increasing p27 expression, and second, that dasatinib induces nuclear
p27 expression specifically by inhibiting its phosphorylation on Thr187 (which is
necessary for it to bind to the Cks1/Skp2 complex and leads to its 26S proteasome
degradation), as well as Ser10, and Thr157 (310). Each of these residue
phosphorylation events have been reported to control the stability of p27 (reviewed in
(311)). This second study also discusses the fact that anti-HER2 antibodies (such as
trastuzumab) upregulate p27 protein levels in breast cancer cells that overexpress
HER2 but decreasing Thr187 phosphorylation of p27 (312). This is in addition to the
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at least six signaling targets and pathways that are modulated by trastuzumab.
Another study proposed that the cisplatin analogue and DNA-damaging agent DAP is
able to induce p27 via a novel mechanism. The authors propose that basal levels of
p27 are recruited into two complexes: CDK4 and CDK2. The CDK2 complex results
in phosphorylation that leads to rapid degradation of p27. They then propose that it is
in fact p21 that is induced and is able to inhibit CDK2 and prevent p27
phosphorylation, thereby stabilization of p27 via preventing its phosphorylation in a
p53-dependant manner via DAP induction (313).
These studies reveal the paradigms of p27 induction, and when they are
compared to the current study of using Skp2 inhibitors in two different regions, the
differences are worth noting. First, there is direct binding of the compounds to Skp2,
(indicated by the mutagenesis experiment) and there are no overt toxicities seen in the
mouse xenograft studies. Second, as the ligands phenocopies the effects of Skp2
genetic deficiency, cellular senescence is achieved in a p53-independent manner
(176). This is significant as advanced cancers often develop resistance to treatments
that induce p53-dependent apoptosis and senescence.

4.3 Future Directions in ZL-25 Development
Here we present novel inhibitors of two different regions targeting different
components/regions of Skp2 and its role in the SCF complex. Both regions were
analyzed using hot spot prediction techniques and the suggested hits were discovered
via virtual screening and were later proven to have biological activity in line with the
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described mechanism. For the Skp1/Skp2 interface, an initial ligand set of over
56,000 compounds was used, and from using two unique docking scoring functions,
we were able to produce a list of 25 compounds that we predicted would have
biological activity. Both sets of lead inhibitors are in the pre-clinical stage, and there
is significant work and study that is needed in their development to advance them into
clinical trials. While ZL-25 has been tested in mouse xenograft models and no overt
toxicity was uncovered in their dosing, a full PK/PD profile should be generated, and
work with medicinal chemists will help to refine the structure to find compounds that
are more effective at lower doses. Also, the IC50 and affinity values for ZL-25 could
certainly be better, and the suggested structures should be synthesized and tested not
only against Skp2, but against other F-box proteins to ensure that specificity towards
Skp2 is not lost.
For the ZM-276 inhibitor, it is certainly more potent than ZL-25, and it is
more specific in targeting p27 to be restored in the nucleus, but at this point in its
development, we don’t have as concrete of evidence that it is precisely binding in the
mode that has been predicted (not as concrete as ZL-25). Therefore, mutagenesis
studies should be carried out to remedy this, as well as crystallographic studies.
Skp2 is an oncogene in the ubiquitin pathway and this finding validates Skp2
as a potential clinical target for which small-molecule inhibitors can be designed.
These novel inhibitors are a first-in-class protein-protein interaction (PPI) inhibitors
of the Skp1-Skp2 complex. Disruption of this complex halts function of the SCF
complex and restores p21/p27. Preclinical work is ongoing to generate a more
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efficient lead, and to identify a suitable cancer for development. This work also shows
that targeting PPIs are a high-risk yet high-reward strategy that opens up a new
domain of potential druggable targets. Computational techniques outlined here can
help minimize this risk by using hot spot prediction to identify targetable regions on
proteins.
As this study identifies two regions on which to target Skp2 with slightly
different mechanisms of action (one disrupting the Skp1/Skp2 interaction, the other
being disrupting the Cks1/Skp2/p27 interaction), it stands to reason that perhaps these
two mechanisms and potential treatment might be synergistic when used as a
combination, especially for cancers that show oncogenic addiction towards Skp2 and
the SCF complex. Certainly, as bortezomib (Velcade) is currently being used for the
treatment of multiple myeloma as a proteasome inhibitor, the inhibitors outlined here
should be considered as a second-line of defense for cancers that are resistant to
bortezomib. However, it should be noted that there is a possibility that resistance can
be possible via a novel proteolytic processing pathway that is independent of
ubiquitination and results in the abrogation of p27 function via the elimination of the
critical cyclin-binding domain (314), and KPC (Kip1 ubiquitination-promoting
complex, which consists of KPC1 and KPC2, a RING-finger domain and a ubiquitinlike domain, respectively) targets p27 for degradation in the G0 - G1 transition while
Skp2/SCF complex targets it in the nucleus in the S and G2 phases (238); so it is
possible that a compensation via KPC might make both inhibitors ineffective. Further
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studies should be carried out to examine if these effects could be problematic for the
development of Skp2 inhibition.
Further work would ideally involve resolving the crystal structure of any of
the Skp2/inhibitor complex (or complexes) which would give a highly affirmative
confirmation of the exact binding pose of these inhibitors, as well as show how Skp2
and the F-box and Cks1 domains respond to binding. Additionally a resolved crystal
structure of the Skp1/Skp2/ZL-25 complex as well as the complete SCF complex with
ligands could indicate how ZL-25 is able to disrupt the preformed SCF complexes
proteins. These structures could be used to conclusively suggest modifications for all
inhibitors that would result in increased binding and efficacy. Additionally other
means by which to measure inhibitor binding such ass ITC or Biacore studies to
quantify the binding affinity and also be used for further design and QSAR studies.
In addition to resolving the binding affinity experimentally, performing
advanced QM/MM molecular dynamics of the complex to attempt to calculate a
binding affinity of the inhibitor. This binding energy would then be compared to a
series of similar compounds to the original (as well as compared relative to any
ITC/Biocore data generated of the protein-ligand complex) and be used as a basis for
qualitative structure-activity relationship (QSAR) studies.
Use of new techniques in functional-genetic approaches can help answer
questions about the best use and classification of these novel inhibitors. One approach
is to examine the response of these inhibitors using a panel of tumor cell lines, and
creating a signature of the sensitivity and resistance, similar to what is available in the
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NCI-60 panel (315). Another approach is to analyze the global changes in the
transcript that are inducted by a test ligand and compare that by known drugs or
defined alterations in the genome (316-319). From this, common changes in
expression are used to cluster small molecules that are similar. Finally, using an
RNAi-based approach combined with machine learning technique can characterize
therapeutic agents, especially in cancer (320). This allows the prediction of a
mechanism of action based on the shRNA signature and can characterize a diverse
range of the categories at high resolution.
One other aspect of this work that should be explored is the question as to how
ZL-25 specifically attenuates the proliferation and survival of cancer cells. It was
shown that ZL-25 has multiple effects on conditions such as: apoptosis, aerobic
glycolysis, and cellular senescence in a p53-independent manner (176), but it is
unclear which of these effects leads most directly to the decreased proliferation and
survival of cancer cells, and if these effects are different depending on the tumor type.
From the NCI-60 data, it has been shown that leukemia cell lines seem to
respond the highest to ZL-25. This would point to these types of cancers as potentially
being a favorable indication to focus on. However, as the ZL-25-treated mouse
xenograft data indicates, solid tumors also show good response rates. Identifying the
precise cancer and cancer subtype are crucial towards maximizing the potential of ZL25 and the other inhibitors targeting Skp2.
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Appendix
1. Docking parameters
For the precise parameters used in GOLD 5.0.1 (CCDC) for the virtual
screening and docking, the primary scoring function used for the virtual screen was
GoldScore, whereas GoldScore and occasionally ChemScore as well as ASP scoring
functions were used to rescore selected ligands for docking analysis and QSAR work.
Also for the virtual screen the setting of "allow early termination" and “soft
potentials” were turned off, and a search efficiency set to 200% was employed to
allow maximal exploration of the hits. For the rescoring and QSAR work, these two
settings were set in the on state.
Configuration file for HiPCDock (AutoDock) used for screening on
Skp2/Skp1 interaction site on pocket1 (pocket 2 used grid_CenterCoordinates="1.962 -100.846 10.708"):
[job]
[dockingSoftware]
dockingSoftwarePackage="AutoDock3"

[autoDockReceptorPreProcessing]
receptor="/scratch2/szhang/SKP2/AutoDock/skip2_2AST_with_H.pdb"

[autoGridParameters]
grid_Center="By Coordinates"
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grid_CenterCoordinates="1.134 -114.378 -1.751"
grid_Points="80 80 80"
spacing="0.25"

[autoDockLigandPreProcessing]
database="/scratch2/lducuny/DataBase/ChemBridge/Chem_Lig"
processLigand="Yes"
autotorsFlags="-m -h -o -a -b -c -M -A +6.5"

[autoDockSearchingParameters]
searchingMethod="Genetic Algorithm"

# geneticAlgorithmParameters
numberOfGARuns="100"
populationSize="100"
maximumNumberOfEnergyEvaluations="500000"
maximumNumberOfGenerations="27000"
maximumNumberOfTopIndividualsThatAutomaticallySurvive="1"
rateOfGeneMutation="0.02"
rateOfCrossover="0.8"
meanOfCauchyDistributionForGeneMutation="0.0"
varianceOfCauchyDistributionForGeneMutation="1.0"
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numberOfGenerationsForPickingWorstIndividual="10"

# energyParameters
externalGridEnergy="1000.0"
maximumAllowableInitialEnrgy="0.0"
maximumNumberOfRetries="10000"

# stepSizeParameters
translation="2.0"
quaternion="50.0"
torsion="50.0"

# outputFormatParameters
rmsClusterTolerance="0.5"
performAClusterAnalysis="Yes"

[outputOptions]
selectionCriterion1Name="Ranking"
selectionCriterion1="5"
selectionCriterion2Name="Binding Affinity"
selectionCriterion2="6"
outputFormat="Text File"
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